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 Abstract 
The term prion was coined by Stanley Prusiner to describe a new biological 
agent that comprises solely of infectious self-replicating proteins. Prions are 
capable to cause lethal neurodegenerative conditions that include scrapie in 
sheep, and Creutzfeldt-Jakob disease (CJD) in humans. They are derived from 
the conversion of a normal, primarily α-helical, cellular prion protein (PrPC), to 
an infectious, β-sheet rich conformer (PrPSc). This proposition was referred to 
as the protein-only hypothesis where the single protein is responsible for a 
wide diversity of structures with different pathogenic properties. For decades 
this hypothesis has motivated the scientific community to decipher the elusive 
features of this new pathogen. However, many unresolved issues still surround 
the process of PrP conversion, and the molecular structure of PrPSc is still 
missing.  
 
The development of the in vitro protein misfolding cyclic amplification (PMCA) 
assay allows for analysis of PrPC to PrPSc conversion.  An excess of PrPC and 
repeated cycles of sonication and incubation are used to amplify PrPSc present 
in the test sample. However, in many labs, including our own, standard PMCA 
is rather hard to control. Moreover, for structural elucidation of prions by NMR-
Spectroscopy the pre-requisite is to obtain extensive amounts of isotope 
labeled recombinant (rec.) prions. For this purpose, a novel method had been 
established in our group called “Selective Shearing Amplification” (SSA), 
where uniform shear forces were used to optimally balance between prion 
growth and prion fragmentation. Moreover, SSA allowed to scale-up the 
reaction volume, which none of the published methods had accomplished so 
far. It was the key objective of this work to establish SSA for the 
conformational selection and homogeneous amplification of prion 
conformations using hamster brain derived prion strains (263K and Sc237) as 
seed and native recombination prion protein as a substrate for the conversion. 
 
At the start, suitable experimental conditions were established to meet the 
central goal of this work. During this initial screening of conditions, the 
formation of recombinant, partially proteinase K resistant PrP (rec. PrPres) was 
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used to successively improve the reaction efficiency. A total of 800 mg of 
unlabelled and of isotopically labelled (15N and 13C/15N) recombinant hamster 
Sc237 and hamster 263K PrP aggregates were produced by SSA. These 
products were further characterization by SSA, negative stain electron 
microscopy, mass spectrometry and solid state NMR spectroscopy. 
 
Using SSA, a wide range of shear forces were scanned, which allowed to 
amplify prion recombinant conformations. In the Sc237 and 263K seeded 
reactions substantial formation of rec. PrPres was obtained, while no 
amplification was observed in non-seeded control reaction run under the same 
experimental conditions. Moreover, the rec. PrPres generated by SSA could be 
infinitely propagated in vitro without any loss of seeding activity. Some of the 
reactions were propagated up to 48 serial passages, where 1:50 serial 
dilutions were used in each step. This corresponds, including the initial brain 
derived seed dilution, to a total dilution of native prions of 2.25 x 10-85. Thus, 
rec. PrPres could readily be generated that is devoid of any brain derived PrPC 
or potential brain derived co-factors.  
 
Using solid state NMR spectroscopy, we characterized conformationally 
selected rec. PrPres and identified three distinct prion conformation present in 
Sc237, but only one conformation present in 263K. Notably the 263K prion 
strain conformation is also present in the Sc237 prion conformational mixture. 
Experimentally, this indicated that overall seed conformations are not altered 
or influenced by shearing mechanisms, but rather conformation can be 
selected even from mixed aggregates. We were also able to record the high 
quality solid state NMR spectra for all identified rec. PrPres conformations. 
Thus, form this work it is evident that a structure determination of prions will be 
possible.  
 
In experimental transmissions, both native hamster strains did not show any 
significant differences in incubation time, glycosylation pattern or brain lesion 
profile. In order to check the infectivity of rec. PrPres we also carried out in vivo 
inoculations into wild type male syrian hamsters. This experiment is still on-
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going at the time of writing this thesis. It might allow for the first time to 
correlate prion infectively to single conformations. 
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Zusammenfassung 
Der Begriff Prion wurde von Stanley Prusiner geprägt, um eine neuartiges 
biologischen Agenz zu beschreiben, dass nur aus selbst replizierenden 
infektiösen Proteinen besteht. Prionen verursachen tödliche 
neurodegenerative Erkrankungen, zu denen Scrapie bei Schafen, BSE bei 
Rindern, und die Creutzfeldt-Jakob Erkrankung (CJD) des Menschen gehören. 
Sie entstehen durch die Konversion des normalen, hauptsächlich  alpha-
helikalen, zellulären prion proteins (PrPC), in ein infektiöses, beta-sheet reiches 
Konformer (PrPSc). Dieser mechanistische Vorschlag wird auch als die 
„Protein-Only Hpothese” bezeichnet, die davon ausgeht, dass ein einziges 
Protein für die Eigenschaften der Prionen, inklusive der diversen Phänotypen 
der Erkrankung, verantwortlich ist. Für Jahrzehnte hat diese Hypothese die 
wissenschaftliche Gemeinschaft motiviert die genauen Eigenschaften diese 
neuartigen Agens zu entschlüsseln. Trotzdem gibt es immer noch eine vielzahl 
unverstandener Eigenschaften der Prionen, und ihrer molekularen Struktur.  
Die Entwicklung des in vitro “protein misfolding cyclic amplification” (PMCA) 
Assay’s erlaubt die Analyse der PrPC to PrPSc Konversion.  Ein Überschuss an 
PrPC und wiederholte Zyklen von Ultraschallbehandlung und Inkubation 
werden dabei benutzt, um PrPSc zu amplifizieren. Jedoch hat sich 
herausgestellt, dass vielen Laboratorien, einschliesslich unseres,  die 
Standard PMCA nur sehr schwer zu kontrollieren ist. Obendrein, würden für 
eine Strukturbestimmung von Prionen mittels NMR-Spektroskopie sehr gross 
Mengen an Isotopenmarkierten recombinanten (rec.) Prionen benötigt. Um 
dies potentiell zu erreichen, wurde in unsere Gruppe eine neuartige Methode 
entwickelt, genannt “Selective Shearing Amplification” (SSA), die gleichförmige 
Scherkräfte nutzt, um Prionen Wachstum und Fragmentierung optimal zu 
balancieren. Zusätzlich erlaubt es SSA, grosse Reaktionsvolumina 
einzusetzen, was mit keiner publizierten Methode bisher möglich war. Das 
Hauptziel in dieser Arbeit war es, SSA für die Selektion und homogene 
Amplifikation von Prion Konformatioen zu etablieren. Dabei sollten die 
Hamster Prionstämme (263K and Sc237) aus Hamstergehirnen als ‘Seed’ und 
natives recombinantes Prion Protein also Substrat verwendet werden. 
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Zu Beginn der Arbeit wurden experiementelle Bedingungen etabliert, um das 
zentrale Ziel zu erreichen. Dazu wurden Bedingungen gesucht, die zur Bildung 
von rekombinantem, partiell proteinase K resistentem PrP (rec. PrPres) führen. 
PrPres Bildung wurde als Indikator verwendet, um die Reaktionseffizienz zu 
verbessern. Insgesamt wurden ca. 800 mg unmarkiertes und 
isotopenmarkiertes (15N and 13C/15N) rekombinantes Hamster Sc237 and 263K 
PrPres mit SSA hergestellt. Diese Produkte wurden dann weiter mit SSA, 
‘negative staining’ Electronenmikroscopie, Massenspektrometrie und 
Festkörper NMR Spektroskopie characterisiert.  
 
Mittels SSA, wurde ein weiter Scherbereicht getestet, der es erlaubte, 
rekombinate Prion Konformationen zu erhalten. In den Sc237 und 263K 
induzierten Rekationen wurden erhebliche Mengen an rec. PrPres generiert, 
während die nicht induzierten Reaktionen keine vergleichbaren Aggregate 
ergaben. Das rec. PrPres konnte unlimitiert seriell in vitro propagiert werden, 
ohne dass die ‘seeding‘ Aktivität sich änderte. Einige Reaktionen wurden bis 
zu 48 Mal seriell propagiert, wobei jeweils 1:50 Verdünnungen verwendet 
wurden. Dies entspricht, einschliesslich der Anfangsverdünnung, einer 
Gesamtverdünnung der nativen Prionen von 2.25 x 10-85. Damit ist es folglich 
möglich, rec. PrPres zu generieren, das frei von PrPC und potentiellen andren  
Co-Faktoren aus Hirngewebe ist. 
 
Mittels Festkörper NMR spectroscopy, haben wir das Konformationell 
selektierten  rec. PrPres charakterisiert. Dabei wurden drei spezifische Prion 
Konformation in Sc237 entdeckt, aber nur eine in 263K. Es ist herauszustellen 
dass diese Konformation auch als Teil der konformationellen Mischung in 
Sc237 vorhanden ist. Experimentell, wurden die Konformationen also nicht 
durch die Scherkräfte induziert, sondern sie können sogar aus Mischungen 
selektiert werden. Wir waren in der Lage hochwertige Festkörper NMR 
Spektren für alle identifizierten rec. PrPres Konformationen zu erhalten. Damit 
wird es aufgrund dieser Arbeit möglich sein, die 3D-Strukturen von Prionen zu 
bestimmen.  
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In experimentellen Transmissionen der nativen Hamster Prion Stämme, sind 
diese aufgrund Ihrer Inkubationszeiten, Glykosylierungsmuster oder 
Hirnpathologie nicht unterscheidbar. Um die Infektiosität  des rec. PrPres zu 
prüfen, wurden Inoculationen in männlichen Goldhamstern durchgeführt. 
Dieses Experiment ist noch nicht abgeschlossen. Potentiell könnten aber zu 
ersten Mal Prion Phänotypen mit einzelnen PrPres Konformationen korreliert 
werden. 
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1 Introduction 
 
1.1 Transmissible Spongiform Encephalopathies 
The vast majority of infectious diseases of humans and animals are caused 
either by parasites, fungi, bacteria, or viruses. A common component to all 
these classes of disease-causing agents is the presence of the molecule such 
as DNA or RNA which is capable of encoding structural or enzymatic 
constituents of the agent. Although components of the host’s cellular 
machinery may be required for replication of the agent (as is the case with 
certain viruses), maintenance of the nucleic acid genome is essential for the 
persistence and spread of the infectious agent.  
An emerging class of diseases is the transmissible spongiform 
encephalopathies (TSEs) or prion diseases that are caused by a yet unknown 
agent. Some of the distinctive features are neuronal vacuolation (spongiosis), 
neuronal death, and explicit glial reactions. In addition, a defining characteristic 
is the deposition, mainly in the brain and lymphoreticular tissues, of an 
abnormal form of host-encoded prion protein (PrP). Also, no adaptive immune 
responses are stimulated upon infection, most likely because the mammalian 
immune system is largely tolerant to PrP of the same species. These diseases 
are atypical in that (i) there can be a long latency period between infection and 
progression to clinical disease (Collinge et al., 2003) and (ii) the diseases can 
manifest with sporadic, genetic, or infectious etiologies (Prusiner, 1998). The 
infectious agents in these diseases exhibit numerous properties which are 
inconsistent with the existence of a nucleic acid genome. Firstly, the TSE 
agent is largely resistant to treatments which destroy nucleic acids such as 
ionizing radiation and nucleases but are sensitive to reagents which destroy 
proteins (Alper et al., 1966). Secondly, no nucleic acid of substantial length 
has ever been found in purified fractions of the infectious agent implying the 
absence of a nucleic acid genome (Kellings et al., 1993; Safar et al., 2005). 
Thirdly, unlike viruses, TSEs do not elicit an immune response (Clarke and 
Haig, 1966). Finally, although certain viral diseases are compatible with a 
    Introduction 
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genetic etiology (i.e. the integration of retroviruses into the host genome or the 
modulation of virus receptors by heritable mutations) spontaneous viral 
diseases cannot be easily rationalized. These results led to the idea that TSEs 
are caused by infectious self-replicating proteins (Griffith, 1967).  
 
Table 1: Main TSE's of human and animals 
 
Table 1: Summary of TSEs that have been described in humans, and mammalian 
species that are relevant for human food safety, i.e. cattle, sheep, goat and elk, and 
the most commonly used experimental animals, i.e. mouse and hamster.  
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1.1.1 Neuropathology and Pathogenesis of Prion Diseases  
There are four principle neuropathological findings for prion disease.(1) 
spongiform change (vacuolar degeneration of brain parenchyma)(Glatzel and 
Aguzzi, 2001), (2) death of neurons (Cronier et al., 2004), (3) astrocytic gliosis 
(DeArmond et al.,2004) (in itself a non-specific reactive response to CNS 
damage but of unusual intensity in prion disease), and  (4) the presence of 
extracellular amyloid plaques in some but not all varieties of prion disease (Will 
et al., 1996).  
The majority of prion diseases (including scrapie, mouse-adapted scrapie, 
BSE, and CJD) are characterized by large amounts of spongiform 
degeneration. Spongiform changes can vary in size and density and range 
from microvacuolation to the fusion of vacuoles to produce status spongiosis. 
The degree of spongiform change does not appear to correlate with neuronal 
loss. Amyloid plaques are also present in the brain in some of the human prion 
diseases, most notably kuru, vCJD and GSS. These amyloid plaques exhibit 
birefringence when stained with Congo red and viewed under polarized light. 
However, regions of pathology within the brain are usually specific to and 
diagnostic of a given prion disease or prion strain (Figure 1). 
PrPSc deposition in the central nervous system is also a hallmark feature of 
prion disease (Prusiner, 1991). The type of PrPSc deposit and its location 
varies among the human prion diseases. PrPSc is also a component of amyloid 
plaques. A characteristic of vCJD and kuru is florid amyloid plaques. They are 
often described as ‘florid plaques’ due to decoration of the perimeter of the 
plaque with regions of spongiform change. PrPSc deposition is also present in 
peripheral tissues of patients with vCJD, primarily in secondary lymphoid 
tissues. 
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To confirm a protein-like agent, the protein had to be purified and 
characterised. Purification of the infectious agent revealed that a single protein 
required for transmission of the disease was present in the brain of infected 
animals (in this case, hamsters infected with an isolate originally obtained from 
a sheep TSE) but absent in brains of healthy animals (Bolton et al., 1982). This 
protein which corresponds to ~ 142 amino acids had a molecular weight of 27-
30 kDa. The accumulation of evidence linking a protein to the TSE agent led 
    Introduction 
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Stanley Prusiner to introduce the concept of a prion (proteinaceous infectious 
particles) and the protein-only hypothesis to explain TSEs in 1982 for which he 
was later awarded the 1997 Nobel Prize in Medicine (Prusiner 1998). 
 
1.2 The ‘Protein-Only’ Hypothesis 
According to the prion, or ‘protein-only’, hypothesis, the central pathogenic 
event of prion disease is the conformational conversion of PrPC into the PrPSc 
isoform (Prusiner, 1998). Strictly interpreted, this hypothesis claims that PrPSc 
is composed solely of misfolded PrP protein and that this misfolded protein 
alone is the infectious agent of prion disease. The generation of PrPSc through 
this misfolding event leads to neurodegeneration by an as yet unidentified 
mechanism. 
 
Several lines of evidence support the idea that the conformational conversion 
of PrPC can be induced by physical interaction with PrPSc. That PrP knockout 
mice whose PrP gene, PRNP, is ablated are resistant to prion infection 
indicates that PrPC is required for PrPSc formation (Bueler et al., 1993; Sailer et 
al., 1994). Additionally, the development of the first in vitro PrPC conversion 
assay by Caughey provided more data supporting a direct interaction between 
PrPC and PrPSc. In Caughey’s cell-free assay, radiolabeled PrPC purified from 
mammalian cells was combined with a stoichiometric excess of unlabeled 
PrPSc and incubated under non-physiological conditions. This reaction resulted 
in the amplification of protease-resistant, radiolabeled PrPSc which could only 
have been derived from the substrate PrPC (Kocisko et al., 1994). More 
recently, researchers using a novel in vitro prion conversion assay called 
protein misfolding cyclic amplification (PMCA) have improved upon Caughey’s 
initial results. Using PCMA, native PrPC can be converted under physiological 
conditions into PrPSc in reactions containing sub-stoichiometric amounts of 
PrPSc (Deleault et al., 2007; Saborio et al., 2001). Together these findings, 
among others, support the hypothesis that PrPSc is formed through an 
autocatalytic process whereby PrPSc interaction with PrPC induces its 
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conformational conversion to form nascent PrPSc. However, definitive proof of 
the ‘protein-only’ hypothesis is still lacking. 
 
Attempts have been made to generate infectious prions in vitro solely from 
misfolded recombinant PrP protein, but to date none of these preparations 
have been infectious to wild-type animals when inoculated intracerebrally 
(Legname et al., 2004). Until an infectious prion can be generated with only 
PrP protein, the ‘protein-only’ hypothesis of prion disease will remain 
unproven. 
 
While it is accepted that PrPC undergoes a conformational change to form 
PrPSc, the precise molecular mechanism of this misfolding event is unknown. 
Several models exist which describe how this process could occur. According 
to the template-assisted model, PrPSc contains the information which is 
required to induce refolding of PrPC upon physical interaction. The misfolding 
event in this model is possibly catalyzed by a cofactor and involves the 
formation of a PrP intermediate during refolding (Abid and Soto, 2006; Cohen 
and Prusiner, 1998). The conversion of PrPC results in the formation of 
homodimeric PrPSc which can interact with other PrPSc dimers to form larger 
aggregates. According to the nucleation-polymerization model, the PrPC 
and PrPSc conformational states exist in equilibrium, but due to instability of 
PrPSc monomers, the PrPC state is favored. However, the formation of 
multimeric PrPSc could stabilize and interact with monomers of spontaneously 
formed PrPSc, leading to the formation of PrPSc polymers (Abid and Soto, 
2006).  
A variation of this model, called the nucleated-assisted model, was recently 
proposed  (Abid and Soto, 2006). In this model, a PrPC conformational 
intermediate forms by interaction with a conversion co-factor. The association 
of these intermediate PrPC molecules induces a second structural conversion 
in PrPC resulting in the formation of stable PrPSc oligomers. It is known that 
molecules of PrPSc readily aggregate both in vitro and in vivo. In vivo, PrPSc 
can form extracellular deposits of amyloid filaments (DeArmond et al., 1985). 
In vitro, protease treatment and detergent extraction of PrPSc induces the 
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formation of rod-like structures (Atarashi et al., 2008). While these 
observations indicate that PrPSc can oligomerize, isolation of a PrP folding 
intermediate during conversion would provide valuable insight into the 
mechanism of prion formation. Recombinant PrP folding intermediates have 
been studied in vitro but it is unknown whether these species are relevant to 
the formation of PrPSc (Apetri and Surewicz, 2003). 
 
1.2.1 Prion Strains  
One aspect of prion biology that is not fully explained by current conversion 
models is the existence of prion strains. Prion strains are distinct isolates 
which display unique biological properties and result in characteristic 
phenotypes when propagated in a given species. Strains can be identified and 
differentiated on the basis of clinical manifestation (such as the “scratching” 
and “drowsy” strains of scrapie when given to goats) (Pattison and Millson, 
1961), differential incubation times (Dickinson et al., 1968), pathological lesion 
profiles (i.e. different strains target different neuroanatomic areas of the brain) 
(DeArmond et al., 1993), the ratio of glycoforms (unglycosylated, 
monoglycosylated and di-glycosylated) within protease-digested preparations 
of PrP (Collinge et al., 1996), the size of the PK-resistant PrP fragment 
(Bessen and Marsh, 1994; Telling et al., 1996), differential reactivity to 
luminescent conjugated polymers (Sigurdson et al., 2007), and other 
biochemical properties such as conformational stability (Legname et al., 2005) 
(Figure 2). The existence of prion strains comprises one of the main 
challenges to the protein -only hypothesis and opponents argue that such 
diversity cannot be encoded in the absence of a nucleic acid (Bruce and 
Dickinson, 1987). Indeed, multiple prion strains can exist for a given PrP amino 
acid sequence suggesting that strain variety is encoded by a different 
mechanism.  
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Mammalian PrP genes are highly conserved, and this hypothesis suggests that 
only a restricted number of different PrPSc conformations are 
thermodynamically permissible and constitute the range of observed prion 
strains (Collinge and Clarke, 2007). Although a significant number of different 
PrPSc conformations might be possible across the range of mammalian PrPs, 
only a subset of these would be allowed within a given mammalian species. 
Substantial overlap between the favoured conformations for PrPSc derived from 
species A and species B might therefore result in relatively easy transmission 
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of prion diseases between these two species, whereas two species with no 
preferred PrPSc conformations in common would have a large barrier to 
transmission (Figure 3). 
 
 
 
According to this model of a prion transmission barrier, BSE would represent a 
thermodynamically highly favoured PrPSc conformation that is permissive for 
PrP expressed in a wide range of different species, accounting for the 
remarkable promiscuity of this strain in mammals. In this Figure, there is 
overlap between the allowable PrPSc conformers between species A and 
species B. This overlap facilitates transmission between these species 
involving the ‘green’ and ‘red’ strains. There is no overlap or allowed 
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conformers between species A or B with species C resulting in a substantial 
transmission barrier between species C and A, or C and B. Passage of strains 
through an intermediate host might allow the adaptation of a particular strain to 
a new host. 
 
1.2.2 Transmission Barrier 
When prions from one species are introduced into a second species, there is 
often a significant species barrier effect which limits the transmission of prions. 
Species barrier effects include prolonged incubation time and inefficient 
transmission (i.e. only a small proportion of inoculated animals get the 
disease). The species barrier has important implications for human health as it 
appears that there is a significant species barrier between humans and CWD 
or scrapie prions. In contrast, BSE prions appear to be rather promiscuous and 
can enter a number of diverse species including humans in the form of vCJD 
(Will et al., 1996). At the molecular level, the species barrier is likely dictated 
by the amino acid sequence of PrP. Between different mammalian species the 
primary transmission of prions is generally inefficient and this effect is 
conventionally called a ‘species barrier’. The amino acid sequence of PrP is 
highly conserved between mammalian species (Schatzl et al. 1995; Wopfner 
et al. 1999), and within the proteinase K resistant core of PrPSc, there are only 
eight amino acid substitutions between mice and hamsters (Figure 4 A). Still, 
mice do not develop prion disease after challenge with hamster prions. 
Transgenic mice that express both hamster PrP and mouse PrP can be 
infected with hamster prions, and then selectively incorporate hamster PrP into 
prion particles (Prusiner et al. 1990). The exclusive expression of a 
mouse/hamster chimeric PrP, termed MH2M, makes mice susceptible to both 
hamster and mouse prions (Scott et al. 1993), and the resulting prions transmit 
disease to both wild-type hamsters and wild-type mice. Thus, the species 
barrier is determined by the primary amino acid sequence of the prion protein, 
and the substitution of only a few amino acid residues can completely alter 
prion transmission patterns. (Prusiner et al., 1990) (Figure 4 B). This is 
remarkable, as there are only few amino acids difference between the two 
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PrPs. Interestingly, the bank vole appears to be susceptible to prions from a 
variety of human prion diseases despite a low degree of sequence homology 
between human and vole PrP (Nonno et al., 2006). This suggests that factors 
other than the PrP amino acid sequence may influence the species barrier.  
 
 
Within a given species, the amino acid of PrP can also profoundly influence 
prion disease susceptibility and incubation times. For example, two 
polymorphisms in the mouse PRNP gene (encoding the L108F and T189V 
polymorphisms in mouse PrP) control prion incubation time (Barron et al., 
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2005;Moore et al.,1998; Westaway et al., 1987). A second example is the 
sheep gene in which polymorphisms at ovine PrP residues 136, 154, and 171 
have a strong effect on susceptibility to scrapie with the VRQ allele being 
associated with increased susceptibility (Westaway et al., 1994). Thirdly, no 
cases of sporadic CJD have been found in individuals with the lysine variant of 
the codon 219 E/K polymorphism in human PrP (Shibuya et al., 1998). Finally, 
the codon 129 M/V polymorphism in the human PRNP gene controls both 
prion disease phenotype (i.e. determining FFI versus gCJD phenotypes when 
in cis to a D178N mutation) and susceptibility to disease (no cases of vCJD 
have been observed in nonmethionine homozygotes (Smith et al., 2004). 
 
1.3 The Prion Protein – Agent responsible for TSE’s 
Following the purification of PrP, the encoding gene (PRNP) was identified. 
Amino acid sequencing of the N-terminus of PrP27-30 was used to derive a 
cDNA clone encoding a host protein, which subsequently demonstrated that 
PrP27-30 was encoded by a single-copy chromosomal gene (Oesch et al., 
1985). The presence of PrP mRNA in the brains of both infected and 
unaffected animals (Barry et al., 1986) provided evidence that PrP could exist 
in two different forms: the normal cellular isoform termed PrPC and the 
disease-associated form, PrPSc (Sc stands for scrapie). In general, PrPSc is 
described as an abnormal isoform of PrP which stimulates conversion of PrPC 
into PrPSc and causes disease. Limited proteolysis of PrPSc  (~33-35 kDa) 
produces a smaller protease resistant molecule of ~ 142 residues designated 
as PrP27-30; under the same conditions PrPC is completely hydrolysed (Basler 
et al., 1986; Oesch et al., 1985; Prusiner, 1984). PrPC can be solubilised by 
low concentration of detergents whereas PrPSc or PrP27-30 remains insoluble 
and polymerises into highly ordered amyloid structures known as prion rods or 
Scrapie associated fibrils (SAF) (Prusiner, 1983; Merz et al., 1983).  
Although insolubility as well as protease resistance can differentiate PrPSc from 
PrPC but studies have shown that these properties  act only as surrogate 
markers, as are high β-structure content and polymerisation into amyloid 
    Introduction 
19 
 
(Jansen et al., 2001; Xiong et al., 2001). Absence of these markers does not 
indicate lack of prion infectivity, therefore selecting an appropriate method of 
sample preparation from scrapie infected brain can influence the sensitivity of 
PrPSc detection because PrPSc is not uniformly distributed in the brain. Some 
of the general distinguishing features of PrPC and PrPSc are listed in Table 2. 
 
Table 2: Differences between PrPC and PrPSc 
  
1.3.1 PrPSc – The Pathological Isoform of Prion Protein 
High resolution structural analysis of PrPSc by NMR spectroscopy or X-ray 
crystallography has been hindered by the aggregated nature and general 
insolubility of purified PrPSc and PrPres. At the secondary structure level it is 
known that PrPSc and PrPres have an increased β-sheet content compared to 
PrPC (Cohen et al. 1993). Studies using antibodies have shown that certain 
epitopes which are exposed in native PrPC are masked in native PrPSc and this 
idea forms the basis for the CDI assay for prions (Prusiner et al. 1998). In 
particular, residues 90 to 120 of hamster PrP are inaccessible in PrPSc 
suggesting that regions within the N-terminal unstructured domain of PrPC are 
conformationally altered in PrPSc (Peretz et al. 1997). In contrast, a recent 
study using hydrogen/deuterium backbone amide exchange found that the β-
sheet core of amyloid fibrils formed from recombinant human PrP(90-231) is 
composed of residues from α-helices 2 and 3 (Surewicz et al. 2007). Upon 
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treatment with proteinase K, PrPSc spontaneously forms amyloid fibrils termed 
prion rods (Prusiner, 1983). Electron microscopy on two-dimensional crystals 
obtained from PrPres has provided low resolution structural data and implies 
the presence of parallel β-helices (Wille et al. 2002). Further studies on these 
crystals has led to a model for PrPSc in which individual units are composed of 
a trimer of PrPSc containing parallel left-handed β-helices (Wille et al. 2007). A 
distinct model for the structure of PrPSc has been obtained by molecular 
dynamics simulations (DeMarco et. Al. 2004). Simulations of hamster PrP with 
the D147N mutation at low pH lead to a β-sheet enriched structure which 
readily forms hexameric protofibrils. Currently there is no consensus as to 
which model, if either is correct and to date there is no high resolution 
structural information available for PrPSc.  
 
PrPSc Formation 
 
In scrapie infected cells, PrPC molecules destined to become PrPSc exit to the 
cell surface prior to conversion into PrPSc (Borchelt et al., 1990; Stahl et al., 
1987). Like other GPI anchored proteins, PrPC appears to re-enter the cell 
through a subcellular compartment bounded by cholesterol rich, detergent 
insoluble membranes, which may be caveolae or early endosomes 
(Gorodinsky and Harris, 1995;Naslavsky et al., 1997;Vey et al., 1996). Within 
this cholesterol rich, non-acidic compartment, GPI anchored PrPC can be 
either converted into PrPSc or partially degraded (Taraboulos et al., 1995). 
Subsequently, PrPSc is cropped at the amino terminus in an acidic 
compartment in scrapie infected culture cells to form PrP27-30 (Xiong et al., 
2001). 
 
Cellular Localization of PrPSc 
 
Investigation of the sub-cellular distribution of PrPSc remains challenging due 
to the lack of antibodies specific to PrPSc. Early studies reported that the 
majority of PrPSc is intracellular, mostly co-localized with Golgi markers and 
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sequestered within lysosomes of scrapie-infected N2a (ScN2a) cells (Borchelt 
et al., 1992; Xiong et al., 2001). Vey et al., demonstrated accumulation of 
PrPSc in CLDs derived from the plasma membrane in ScN2a cells (Vey et al., 
1996). In prion-infected brains, PrPSc accumulates at the plasma membrane 
(Sim and Caughey, 2009) and occasionally in structures which contain the 
cation-independent mannose 6-phosphate receptor, ubiquitin-protein 
conjugates, a-glucuronidase, and cathepsin B, termed late 
endosomal/lysosomal compartments (Arnold et al., 1995). More recent reports 
have described the accumulation of PrPSc in various cellular compartments: 
the perinuclear Golgi region of neurons in scrapie-infected transgenic mice 
(Barmada and Harris, 2005); the late endosomal compartments in infected 
GT1-7 and N2a cells (Pimpinelli et al., 2005) and the cell surface and early 
endocytic/ recycling vesicles in hippocampal neurons (Godsave et al., 2008). 
In SN56 cells and hamster cortical neurons, exogenous Alexa-labelled PrPSc 
internalized into vesicles which stain positive for late endosomal/lysosomal 
markers (Magalhaes et al., 2002) .Mange et al. showed accumulation of PrPSc 
in the nuclei of prion-infected N2a cells (Mange et al., 2004) by demonstrating 
that nuclear PrP interacts with chromatin in vivo. Several in vitro studies have 
shown accumulation of PrPSc -like conformers (prion protein conformers that 
are not necessarily infective) in the ER (Ivanova et al., 2001; Lehmann and 
Harris, 1997) Golgi and plasma membrane of infected cells (Ivanova et al., 
2001). Under certain conditions, PrPSc -like conformers have been reported to 
accumulate in the cytosol (Ma and Lindquist, 2002) and there is also evidence 
for cytosolic PrPSc-containing aggresomes in prion-infected cells following 
proteasome inhibition (Kristiansen et al., 2005). The tentative conclusion from 
these studies is that PrPSc is widely distributed within infected cells, although 
improved methods for in-situ detection of PrPSc are clearly needed to establish 
the relative proportion of the protein in these cellular sites. 
 
1.3.2 PrPC – The Normal Cellular form of Prion Protein 
Human PrP is initially expressed as a 253 amino acid polypeptide (Figure 5). 
The N-terminus of PrPC contains a signal sequence directing it to the 
endoplasmic reticulum (ER) (Caughey et al., 1989). Once in the ER, this signal 
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sequence is removed and PrPC undergoes several stages of post-translational 
modification. An approximately 18 amino acid hydrophobic C-terminal 
sequence directs the addition of a GPI anchor while in the ER, and this GPI 
sequence is simultaneously cleaved from PrPC resulting in the mature form 
PrPC which is approximately 209 amino acids in length, depending on the 
species (Stahl et al., 1987). PrPC can undergo N-linked glycosylation at two 
sites, initially via the addition of high mannose glycans in the ER which is 
followed by carbohydrate modification in the Golgi (Haraguchi et al., 1989). 
Thus, PrPC can exist in three glyoforms: unglycosylated, monoglycosylated, 
and diglycosylated. The structures of PrPC from various species have been 
determined and are remarkably similar: the N-terminus is unstructured in 
solution whereas the C-terminal domain consists of a three α-helix bundle with 
two short β-strands. Additionally, a single disulfide bond is introduced between 
cysteine residues located within the C-terminal domain (Turk et al., 1988). To 
date, no differences in post-translational modification between PrPC and PrPSc 
have been identified. 
 
Another feature of the cellular prion protein is an N-terminal octarepeat region 
consisting of five repeats of the sequence PHGGGWGQ in the case of human 
PrP. The octarepeat region is notable for several reasons. Firstly, the histidine 
residues are capable of binding copper with four copper-binding sites located 
within the octarepeat region (Brown et al., 1997) and copper is known to 
induce endocytosis of PrPC (Pauly and Harris, 1998). Secondly, expansions of 
the octarepeat domain (with up to fourteen total repeats) are known to cause 
genetic prion disease classified as either gCJD or GSS (Krasemann et al., 
1995) and expression of this mutant protein in transgenic mice causes a non-
transmissible neurological syndrome (Chiesa et al., 1998). The second notable 
region is the hydrophobic tract prior to the beginning of the structured domain. 
This sequence is well conserved amongst PrPC sequences from a variety of 
species. Mutations within this sequence can increase the formation of Ctm PrP 
(a transmembrane topological variant of PrP in which the C-terminus is luminal 
and the N-terminus is cytoplasmic) which has been linked to 
neurodegeneration (Hegde et al., 1999). Furthermore, as N terminal deletions 
in PrPC invade this domain, the truncated proteins become increasingly toxic to 
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transgenic mice (Shmerling et al., 1998). The extreme N-terminus of PrP (the 
basically-charged region beginning at residue 23 of mouse PrP) is important 
for its proper trafficking in the cell (Sunyach et al., 2003). Upon suramin-
induced misfolding of PrPC, constructs lacking this region remain on the cell 
surface, indicating a defect in the trafficking and recycling of misfolded proteins 
(Gilch et al., 2004).   
 
 
 
Cellular Biology of PrPC 
 
Investigating the biosynthesis, posttranslational processing, cellular 
localization, and trafficking of PrPC and PrPSc allows examination of the 
properties of PrP in the setting of native cellular structures. The function of 
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PrPC and co-factors that are likely to be critical in mediating the efficient 
conversion of PrPC into PrPSc can only be elucidated in detail in a cell culture 
model system. PrPC is a glycoprotein, normally attached to the surface of 
neurons, especially synaptic membranes, and glia cells of the brain and spinal 
cord in all mammals via a glycophosphatidylinositol (GPI) anchor (Moser et al., 
1995; Stahl et al., 1987). The expression pattern of PrPC is diverse and 
developmentally regulated in skeletal muscle, kidney, heart, secondary 
lymphoid organs and the CNS, suggesting a wide-ranging and conserved 
function of the protein (Aguzzi and Polymenidou, 2004; Bendheim et al., 1992; 
Caughey et al., 1988; Dodelet and Cashman, 1998; Moser et al., 1995). 
 
Cellular Localization of PrPC  
 
To date, the precise cellular localization of PrPC in neurons remains elusive. 
Most studies have shown that PrPC is predominantly present in detergent-
resistant microdomains (DRM or lipid rafts) on the plasma membrane, in 
particular in the axon or synaptic membrane (Mironov et al., 2003). Other 
putative sites of PrPC localization are: the ER (Sarnataro et al., 2004), the 
Golgi, endolysosomes  (Magalhaes et al., 2002), exsosomes (Fevrier et al., 
2004), the plasma membrane (Sarnataro et al., 2002), clathrin coated pits 
(Sunyach et al., 2003), caveolae (Zahn et al., 1997), lipid rafts (Vey et al., 
1996), and the cytosol. Although PrPC is known as a cell-surface GPI-
anchored protein, it does not remain on the cell surface; it constitutively cycles 
between the plasma membrane and an endocytic compartment from which 
most of the PrPC is recycled back to the cell surface (Shyng et al., 1993). More 
than 90 % of surface PrPC is internalised within two minutes and returned to 
the cell surface within six minutes (Sunyach et al., 2003). During this process, 
PrPC is cleaved near residue 110, probably in an acidic cellular compartment 
(Merz et al., 1981). The biological role of PrPC internalization is unknown, but 
studies have demonstrated that internalization is induced by copper and zinc 
ions and thus could have a physiological function in chelating extracellular 
copper ions or in modulating the signal activity of the protein (Pauly and Harris, 
1998; Watt and Hooper, 2003). Understanding the endocytic itinerary of PrPC 
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is fundamental, since both general inhibition of endocytosis (Godsave et al., 
2008; Gohel et al., 1999) and/or a direct modification of the internalization 
route of PrPC by replacing the GPI anchor with a transmembrane sequence 
containing a coated pits localization motif (Fournier et al., 2000) affect the 
infection and the conversion processes(Beranger et al., 2002; Borchelt et al., 
1992; Xiong et al., 2001). 
 
The mechanism of PrPC uptake is currently debated.  Dynamin, clathrin-coated 
pits, rafts and caveolae appear to play an important role. Immunogold 
localization of PrPC in clathrin coated pits and vesicles suggest that PrPC 
internalizes via clathrin-mediated endocytosis (Sarnataro et al., 2009; Sunyach 
et al., 2003). Magalhaes and co-workers also demonstrated that cells 
transfected with a dominant negative mutant of dynamin I (K44A), which 
blocks fission of invaginated coated pits from the plasma membrane, inhibit 
PrPC endocytosis suggesting that PrPC is internalized via a dynamin 
dependent pathway (Magalhaes et al., 2002). A basic amino acid motif in the 
N-terminal half of PrPC polypeptide chain was shown to be essential for 
efficient clathrin-mediated endocytosis as deletion within this region diminishes 
internalization of PrPC (Sunyach et al., 2003). This finding led to the proposal 
that PrPC binds through this N-terminal region to a ‘PrPC receptor’, a 
transmembrane protein, that has a coated-pit localization signal causing it to 
enter the clathrin-dependent internalization pathway. In Chinese hamster ovary 
cells, which express caveolin-1, PrPC is absent in clathrin-coated pits and 
vesicles, instead being localized in caveolae at the trans-Golgi network, the 
plasma membrane and in interconnecting chains of endocytic caveolae (Zahn 
et al., 1997). To date, however, no caveolae have been identified in adult 
mammalian neuronal cells, suggesting this pathway is unlikely to be relevant to 
prion trafficking in neurons (Morris et al., 2006). An alternative hypothesis 
regarding PrPC internalization involves lipid rafts, also called caveolae-like 
domains (CLDs), which have similar lipid composition to caveolae but lack 
cavealin-1 (Sabharanjak et al., 2002). Studies have suggested that PrPC 
internalization can be raft-dependent and/or raft-mediated depending on the 
cell type. Sarnataro and colleagues demonstrated that PrPC is internalized in 
Fischer rat thyroid (FRT) cells via raft-mediated endocytosis. Cholesterol 
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depletion and inactivation of cell division cycle 42 (Cdc-42) in FRT cells 
impaired uptake of PrPC, suggesting a role for lipid rafts in PrPC endocytosis 
(Sarnataro et al., 2009). 
 
Physiological Function of PrPC 
 
PrPC is a highly conserved protein that is found in all tetrapods and in birds 
(Wopfner et al., 1999). Moreover, the structure of PrPC from different species is 
highly similar (Calzolai et al., 2005), suggesting that the function of PrPC is 
evolutionary conserved. Lately a homologue to prion-protein was identified in 
the pufferfish (Fugu rubripes), showing high homology with mammalian PrP 
sequences (Oidtmann et al., 2003; Suzuki et al., 2002) and Gibbs et al. 
described for the first time, the presence of normal isoform of amyloid protein 
(PrP) in brains of spawning salmon (Gibbs and Bolis, 1997). Subsequently, 
further cDNA sequences were identified in other fish species (zebra fish, 
common carp, stickleback, and rainbow trout) (Maddison et al., 2005; Rivera-
Milla et al., 2006).  
The most prominent phenotype of PrPC - deficient mice is their resistance to 
prion infection, but no other striking phenotype was initially observed (Bueler et 
al., 1992; Manson et al., 1994). Therefore, it has been suggested that the loss 
of PrPC function may be compensated by other proteins. A closer analysis of 
PrP0/0 mice revealed several subtle phenotypic alterations, such as altered 
circadian activity rhythms and patterns (Tobler et al., 1996), modified 
responses to oxidative stress due to reduced activity of Cu/Zn superoxide 
dismutase, functional changes in the glutamatergic system (Coitinho et al., 
2002; Khosravani et al., 2008), peripheral chronic demyelinating 
polyneuropathy (Bremer et al., 2010), reduced levels of anxiety (Nico et al., 
2005), age-related motor behavioral and neuropathological deficits (Nazor et 
al., 2007; Rial et al., 2009), retarded regeneration of adult muscle (Stella et al., 
2010), and alterations in synaptic function (Collinge et al., 1994). Based on 
these findings, several physiological roles have been attributed to PrPC, such 
as modulation of synaptic transmission and neuronal excitability, protection 
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against oxidative stress, and a role in cell differentiation and neuronal 
adhesion (Linden et al., 2008). These findings strongly support the notion that 
physiologically active PrPC is part of signaling cascades implicated in various 
cellular processes. 
 
Structure of PrPC  
 
It has been indicated that PrPC and PrPSc are chemically identical; however, 
the biophysical features of PrPSc are significantly different from PrPC in respect 
to solubility, structure, fibril formation, proteinase K resistance and other 
features. These differences could be either a consequence of ligands bound to 
one isoform but not to the other or a consequence of a different secondary and 
tertiary structure of PrPC and PrPSc, respectively (Riesner, 2003). At the 
secondary structure level it is known that PrPSc and PrPres have an increased 
β-sheet content compared to PrPC (Pan et al., 1993). Fourier-transform infra-
red (FTIR) spectroscopy and circular dichroism (CD) were employed to 
investigate the secondary structure of PrPC and PrPSc. PrPC contains ~40% α- 
helix and ~3% β-sheet (Pan et al., 1993; Pergami et al., 1996). Remarkably, 
PrPSc contains ~30% α-helix and ~45% β-sheet. This finding supported the 
unorthodox conclusion that the same PrP polypeptide could adopt two distinct 
conformations.  
 
Brain derived PrPC poses several disadvantages for three-dimensional 
structural determination by X-ray or NMR spectroscopic methods. Firstly, the 
amount of material available was too small, the samples were not sufficiently 
pure, and the concentration was also less. These problems prompted the need 
for expression and purification of recombinant PrP labeled with either 15N or 
13C. 
 
Using recombinant PrP, Riek et al. (Riek et al., 1996) solved the structure of 
the C-terminal part of PrP, i.e. amino acids (121–231) which consists of three 
α-helices (amino acids 144–154, 175–193 and 200–219) and a small 
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antiparallel β-sheet (amino acids 128–131 and 161–164) (Figure 6). Later, 
structure of ‘full-length’ PrP (i.e. amino acids 23–231) was also analyzed which 
showed that the C-terminal part (i.e. amino acids 126–231) contained the 
complete globular part of the structure, whereas the N-terminus (i.e. amino 
acids 23–125) was more or less flexible (Donne et al., 1997; Riek et al., 1997; 
Zahn et al., 2000). In the globular domain, a disulphide bridge connects helix 2 
and helix 3 (Lopez Garcia et al., 2000).The region between the β-sheet and 
helix 2 (amino acids 166–171) could be determined with less accuracy 
possibly because of some structural flexibility. This region, however, is of 
particular functional interest. Different lines of evidence such as antibody 
binding, transgenic animals with mutations in that region, binding of the 
hypothetical factor X, etc. argue that the species barrier might be localized in 
that region. Furthermore, the minor differences in the structure of mouse and 
hamster PrP on the one hand and of bovine (Lopez Garcia et al., 2000) and 
human PrP on the other are restricted to that part of the molecule. 
 
The NMR-structure of PrP is a monomeric structure. Several reports in the 
literature indicate that PrP in its α-helical structure can form dimers under 
physiological or close to physiological conditions (Jansen et al., 2001; Meyer et 
al., 2000). Dimers in solution show the intact intramolecular disulphide bridge. 
Consequently, dimerization is not induced by oxidizing the disulphide bridge 
and reforming it in an intermolecular structure. The latter situation was, 
however, found in a recent crystal structure of a dimer of PrP (120–231)(Knaus 
et al., 2001); dimers were formed by domain swapping and intermolecular 
disulphide bridging. Whether this structure is a consequence of the long-time 
crystallization, or might indicate a physiological state, cannot be stated at 
present. 
 
As mentioned above, PrPSc or PrP27–30 are not accessible to structural analysis 
by NMR or X-ray analysis because of their insolubility. Attempts were made 
(Pan et al., 1993) to use the structure described above as a starting model, 
where α-helices were changed into β-sheets to develop a model for PrPSc. 
These models assume that helix 2 and helix 3 are unchanged in accordance 
with antibody binding data, but they are incomplete in the sense that they are 
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models for isolated molecules whereas PrPSc as well as PrP27–30 were found 
only in aggregated forms. Thus, one has to assume that the PrPSc structure is 
stabilized by intermolecular interactions. 
 
 
 
A new approach was followed by Wille and coworkers to prepare two-
dimensional crystalline-like arrays of PrPSc - or PrPSc -like molecules (Wille et 
al., 2002). Those samples were studied by electron microscopy and, because 
of the crystalline-like arrangement; images could be reconstructed from the 
repetitive unit with fairly high resolution. A hexagonal symmetry was visible, 
but it could not be decided whether one unit is built from 3 or 6 molecules. The 
electron density map could be fitted best if, instead of β-sheets, a β-helix was 
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assumed. The structure of the β-helix type is known from other fibrillar 
proteins; spectroscopically, β-sheets and β-helices cannot be differentiated, so 
that the new model would not contradict earlier spectroscopic studies. In 
summary, the β-helical N-terminus is located in the inner part of the hexagonal 
unit, with the helices 2 and 3 at the outer side and the glycosyl-groups pointing 
into the space between the hexagonal units.  
 
Recent experimental studies using mass spectrometry analysis coupled with 
hydrogen-deuterium exchange indicate a PrPSc conformation completely 
different from PrPC (Smirnovas et al., 2011), which is in disagreement with the 
“β-helical” and “spiral” models, in which PrPSc retains substantial amounts of 
native α-helices (DeMarco and Daggett, 2004; Govaerts et al., 2004). 
 
1.4 Methods for the in vitro conversion of Prions  
A major issue in coping with any infectious disease is the ability to detect the 
responsible pathogen. In case of TSEs, it is evident that the pathogen is a 
misfolded multimeric form of the host’s prion protein (PrP). This infectious 
protein, PrPSc, can instigate its own propagation by binding to its normal 
counterpart, PrPC, and inducing its conversion to a form that tends to be higher 
in beta sheet content, polymeric, and protease resistant (Figure 7). The lack of 
the nucleic acid genome negates the possibility of prions by nucleic acid 
amplification methods such as PCR. The fact that the infectious agent is 
composed mainly of a host protein also restricts the use of antibody based 
detection methods. However, the seeded/templated conformational conversion 
can be exploited for detection of prion in vitro.  
    Introduction 
31 
 
 
 
 
 
 
Table 3 summarises recent developments in the characterisation and detection 
of prions using assays based on seeded conversion of PrPC. 
Table 3: In vitro conversion assays for Prions 
 
 
 
Figure 7: PrPSc and PrPC are mixed and incubated, allowing the 
misfolding of PrPC, which permits the incorporation and growth of PrPSc 
aggregates. After incubation, samples are submitted to fragmentation in 
order to fragment PrPSc polymers, thereby generating new free ends 
suitable for continued prion replication. This process is cyclically repeated 
in order to produce an exponential amplification of PrPC conversion.  
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1.4.1 Cell Free Conversion assays (CFC assay) 
The ability of PrPSc to induce the conversion of PrPC to PrPres was initially 
demonstrated in cell free reactions in which brain derived PrPSc was incubated 
with radioactively labelled PrPC, which, under suitable conditions, bound to the 
PrPSc and became similarly partially protease resistant. These cell free 
reactions were shown to be highly specific in ways that correlated with prion 
transmission barriers and strains (Caughey et al., 1999). However, the newly 
generated PrPres was usually substoichiometric relative to the initial PrPSc seed, 
and was not associated with new infectivity. (Shaked et al., 1999). As a result, 
these cell free conversion reactions were not suitable for sensitive detection of 
PrPres and prions. 
 
1.4.2 Protein Misfolding Cyclic Amplification (PMCA) and Recombinant 
Protein Misfolding Cyclic Amplification (rPrP-PMCA) 
In 2001 Soto and colleagues described a new cell free prion conversion assay 
called Protein Misfolding Cyclic Amplification (Castilla et al., 2006) which has 
greatly improved efficiency, continuity, and sensitivity compared to the CFC 
reactions. In the typical PMCA reaction, crude brain extracts are used as a 
source of PrPC which is induced to convert by prions in the test tube sample. 
Under these conditions, PrPres can be amplified to detectable levels.   
In 2007, Atarashi et al. tried to replace the substrate from normal brain 
homogenate to rec. PrP using the standard PMCA set-up.(Atarashi et al., 
2007). This method which they called rPrP-PMCA was able to detect as little 
as 50 ag of PrPSc and can also differentiate between scrapie – infected and 
uninfected hamsters using 2 µl of cerebrospinal fluid.      
Recently Chen et al. have reported a “Quantitative PMCA” (qPMCA) method to 
estimate the concentration of minuscule amounts of prions in biological 
samples. This approach is based on direct correlation between the extent of 
PrPSc in a given sample and the number of rounds necessary for its detection. 
More recently, Wang and colleagues (Wang et al., 2010) described the 
generation of a recombinant prion with features typical of in-vivo generated 
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prions using three components: rPrPC, POPG (1-palmitoyl-2-
oleoylphosphatidylglycerol), and RNA. Following intracerebral inoculation in 
wild type mice the clinical stage of disease was reached at ~ 150 days. 
Biochemical characterisation of PrPres generated, as well as the clinical 
symptoms, histopathology, and second passage behaviour induced by its 
inoculation strongly supported the conclusion that they had generated TSE 
infectivity using these three molecular components. 
A related study by Kim and colleagues (Kim et al., 2010) reported that prions 
able to induce disease in wild type hamsters can be generated from purified 
bacterial  rPrPC in absence of any mammalian cofactors using prion seeded 
rPMCA. This rPMCA product showed variable attack rates upon inoculation 
into hamsters and therefore contained low levels of infectivity (incubation time 
from 119 to 401 days) on the first passage. However, upon second passage all 
animals became ill with an average incubation period of about 80 days. Lesion 
profiling indicated that rPMCA had altered the strain characteristics of prions 
(263K strain) that were initially used to seed the serial rPMCA reactions. 
However, various research groups including Nishina et al.(Nishina et al., 
2006), have reported that such reactions have resulted in a limited yield of the 
PrPSc product. 
It has also been stated that it is not possible to use standard PMCA method for 
conversion of rec. PrP to PrPSc. The reason for this limitation was believed to 
be the absence of some brain derived factors which are essential for prion 
propagation. Additionally, lack of glycosylation and glycosylphosphatidylinositol 
(GPI) anchor in rec. PrP expressed from E.coli also contribute to the difficulty 
in amplifying reactions with rec. PrP (Eiden et al., 2006; Iniguez et al., 2000; 
Kirby et al., 2003). 
 
1.4.3 Amyloid Seeding Assay (ASA) for Prions 
Colby et al. developed a new amplification assay for prions that utilises 
thioflavin T to detect amplification using the fluorescent plate reader. (Colby et 
al., 2007). Thioflavin T is a dye that displays enhanced fluorescence upon 
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binding to amyloid fibrils. Through this assay, it was demonstrated that multiple 
prion strains could seed the polymerization of rec. PrP into an amyloid – the 
feature which could be beneficially used for the detection of prions in biological 
samples. This method uses partially purified prions as seeds which is 
accomplished by phosphotungstate (PTA) precipitation and rec. PrP stored in 
6M guanidine hydrochloride as a substrate. The final guanidine hydrochloride 
concentration in the reaction (0.4 M) is such that the substrate is likely in a 
partially unfolded/destabilised state. Other reaction parameters include 
incubation at 37ºC, the presence of a 3 mm glass bead in each well to 
enhance agitation, and continuous shaking of the plate. This assay gives a 
totally new dimension to prion amplification by being a sensitive and a speedy 
way for prion detection. 
However, there’s also a limitation to this assay. Due to variation in the kinetics 
of ThT positive fibril formation, a number of replicates per sample have to 
analyse each time. Additionally, this assay often causes formation of 
spontaneous (non-seeded) rec. PrP fibrils.  
 
1.4.4 Quaking Induced Conversion Reactions (QuIC) 
To overcome the shortcomings of rPrP-PMCA, a new method was devised 
called “QUIC” for quaking induced conversion where sonication is substituted 
by recurrent cycles of shaking and incubation.(Atarashi et al., 2008). The initial 
QuIC reactions abbreviated as standard QuIC or S-QuIC were carried out on a 
thermoshaker with optimized concentrations of detergents. After systematic 
standardization of reaction parameters like shaking condition, detergent 
concentrations, incubation time and reaction temperature, the QuIC method 
was able to distinguish between spontaneous (non-seeded) and the seed 
specific reactions. The only limitation with these kinds of assays, which till date 
has not been resolved, is the time associated to detect the amplified product 
which is only possible through western blotting.  
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1.4.5 Real Time Quaking Induced Conversion Reactions (RT-QuIC) 
Towards addressing the issues which lag behind ASA and S-QuIC, Atarashi et 
al. (Atarashi et al., 2011) developed a new assay called Real-Time (RT) QuIC 
which is an amalgamation of both S-QuIC and ASA where the readout has 
been made easier by using Thioflavin T (ThT). In RT-QuIC, the progress of the 
QuIC reaction can be monitored continuously in a shaking, temperature 
controlled fluorescent plate reader. As with ASA, the multiwell plate format 
makes the RT-QuIC more amenable to high-throughput testing of samples. 
Using this “real time” version, 200 cerebrospinal fluid samples from sCJD or 
Alzheimer’s disease patients were tested and the sensitivity was greater than 
80%. However, the sensitivity for vCJD may be somewhat lower (Peden et al., 
2012). 
The latest adaptation incorporates an antibody binding step to concentrate the 
prions in the sample in the assay known as Enhanced QuIC (eQuIC). Within 
this approach, there is a remarkable increase on sensitivity for detecting vCJD 
(down to 2 attograms per mL of protein) including detection in blood samples 
spiked with vCJD prions (Orru et al., 2011). 
 
1.4.6 Questions still remain to be answered  
Several questions in prion biology are still unanswered. In particular, the 
molecular mechanism behind PrPC to PrPSc conversion is unclear and the 
structure of PrPSc is still missing. In order to obtain the structural information of 
mammalian prions it is necessary to obtain substantial amounts of isotopically 
labelled recombinant prions. However, none of the methods published so far 
are capable of producing a prion sample in milligram’s amount within a day.  
Therefore, it is necessary to develop a suitable method which is capable of 
amplifying prions under in vitro conditions in a homogenous and reproducible 
manner. Furthermore, the method should hold the potential for propagating 
prions in any desirable volume without affecting the rate of amplification or loss 
in the yield. Establishing such a method might resolve all the above mentioned 
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problems and may provide new insights into the role of prion proteins in human 
health and disease. 
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2 Aim and Objectives 
The PrPC → PrPSc conformational conversion in relation to the pathological 
effects of prions is poorly understood.  The structure determination of PrPSc 
continues to be a major challenge in prion research. The mechanism of 
propagation of these infectious agents will not be fully understood until their 
structure is solved. However, the elucidation of prion structure by NMR 
spectroscopy requires extensive amounts of isotope labelled recombinant 
(rec.) prions. Since none of the published methods has thus far accomplished 
the task, a novel method called “Selective shearing amplification (SSA)” was 
developed in our lab to overcome this key bottleneck. 
The first objective of this work is to develop a standardized approach using 
SSA for the amplification of hamster brain derived prions, in vitro, using 
exclusively recombinant PrPC as a substrate. Key parameters that might 
influence this process will be investigated. In particular, these include (i) the 
PrPSc, i.e. seed, concentration, (ii) the PrPC concentration, i.e. substrate, (iii) 
the processing conditions, (iv) the buffer composition, and (v) also the 
amplification rates. All these parameters might significantly impact the degree 
of amplification achieved, and most importantly the quality of the obtained 
product. Once the initial optimization has been achieved, Sc237 and 263K 
hamster prions will be serially propagated in vitro in order to dilute the initial 
brain derived seed below the detection limit.  
The second objective of this work is to characterize in vitro propagated rec. 
PrP aggregates by (i) SSA to confirm PrPres conformational in vitro selection, 
(ii) negative staining electron microscopy to detect morphological diefference, 
(iii) Mass spectrometry to identify major proteinase K (PK) resistant peptides, 
and (iv) solid state NMR spectroscopy to identify specific conformational 
differences at atomic resolution.  
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3 Materials and Methods 
 
3.1 Materials 
3.1.1 Instruments 
A list of all instruments used during this thesis can be found in Table 4 
Table 4: Instruments 
 
SSA Array 
 
 
Electrophoresis chamber 
(SDS-PAGE) 
 
Self-made 
Patent no.  EP2489427(A1) - 2012-08 22 
 
XCell4 SurelockTM Midi-Cell (Invitrogen) 
 
Autoclave 
 
HAST 4-5-6 (Zirbus) 
 
shear-generators for 
mechanical SSA 
 
Silent crusher S - Generator 7 F (Heidolph) 
 
Incubator 
 
FunctionLine (Heraeus) 
pH-Meter MP 230 (Mettler-Toledo) 
Photometer Ultraspec 3,000 (Pharmacia Biotech) 
Thermoshaker Thermomixer comfort (Eppendorf) 
Dry bath FB15103 (Fisher Scientific) 
Microcentrifuge 5417 R (Eppendorf) 
Mid bench centrifuge 4K15C (Sigma) 
Deionized water supplies Milli-Q Plus (Millipore) 
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3.1.2 Chemicals 
All laboratory chemicals were of p.a. grade and purchased from Sigma-Aldrich 
(Taufkirchen, Germany), Merck (Darmstadt, Germany), Carl Roth GmbH 
(Karlsruhe, Germany), Serva (Heidelberg, Germany), Biozym Diagnostik 
(Hameln, Germany) or AppliChem (Darmstadt, Germany). 
3.1.3 Consumables 
All consumables were purchased from Becton Dickinson, Eppendorf, Greiner, 
Macherey-Nagel, Nunc, Thermo Fisher Scientific, TPP or Roth, unless 
otherwise stated. 
3.1.4 Shear Generators 
Generator 7 F – Heidolph 
 
Cat. Number: 596-07010-00  
 
3.1.5 Reaction Tubes 
Reagenzröhrchen 7F/20ml – Heidolph 
Cat. Number: 596-00007-00-0 
 
3.1.6 100 kDa Filter for Protein 
Macrosep Advance Centrifugal Device 100K MWCO − Pall Corporation 
Cat. Number: MAP100C37  
 
3.1.7 Kits 
Pierce® Silver stain kit − Thermo Fisher Scientific 
Cat. Number: 24612 
 
3.1.8 Protein Marker 
SeeBlue® Plus2 Pre-Stained Standard – Invitrogen 
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3.1.9 Enzymes 
100X N2 supplement – Invitrogen 
Proteinase K (PK) – Merck 
 
3.1.10 SDS Gels  
NuPAGE® Novex 4-12% Bis-Tris Midi Gel – Invitrogen 
Cat. Number: WG1403BOX 
 
3.1.11 rec. Hamster PrP (23-230) 
The protein solution should be filtered through a 100 kDa filter (PALL) 
immediately before use.  
 
3.1.12 Additional Agents 
4 x LDS sample buffer − Invitrogen 
20 x MES running buffer − Invitrogen 
 
3.1.13 Prion Strains 
Prion strains which have been used to seed in vitro SSA reactions are listed 
below (Table 5).  
Table 5: Prion Strains 
 
Sc237 
 
Dr. Eckhard Flechsig and  Prof. Dr. Michael Klein  
(Institute of Virology, University of Würzburg)  
263K Bruce W. Chesebro, M.D.  
(National Institutes of Allergy and Infectious Diseases, Hamilton) 
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3.1.14 Buffer Solutions 
The buffers used this thesis are listed in table 6. 
Table 6: Buffer Solutions 
 
2 x Proteinase K (PK) 
digestion buffer  
 
2% (w/v) N-Lauroylsarcosin in 1x PBS  
PK solution 0.5 μg/ml PK in 2 x PK Digestion buffer 
10 x PBS for SSA reaction  Na2HPO4. 2H2O                           100    mM 
NaH2PO4. H2O                             100    mM 
NaCl                                            1300  mM 
pH                                                6.9 
4 X Reaction Buffer 10% SDS stock                              40  µl/ml 
10% Triton X-100 stock                 40  µl/ml 
10 X PBS stock                             400 µl/ml 
Milli-Q H2O                                   520 µl/ml 
 
Perfusion Buffer (PB)  
 
EDTA                                            5.00 mM 
KCl                                                2.68 mM 
KH2PO4. H2O                                1.76 mM 
Na2HPO4. 2H2O                            8.09 mM 
NaCl                                              137  mM 
pH                                                 7.4 
Filter with 0.2 µm membrane 
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3.2 Methods 
3.2.1 Recombinant PrP Expression and purification 
 
Expression 
Recombinant Syrian hamster full-length prion protein (23–231) was expressed 
in Escherichia coli and purified as described previously (Zahn et al., 1997). 
DNA Sequences coding for hamster (residues 23–231) were amplified and 
ligated into the pETRO_shPrP(23-231) vector. After transforming the plasmids 
into BL21 (DE3) cells, we expressed the PrPc using the auto-induction media. 
Auto-inducing cultures were incubated overnight 37 °C (250 rpm). Next day, 
cultures were spun down at 7150 g for 7 min. (4°C). Obtained pellets were 
either directly processed for purification or frozen at -80°C for later use.  
 
Purification 
 
Recombinant PrP was produced with an N-terminal His-tag to allow for specific 
binding to Ni-NTA (nitrilotriacetic acid) sepharose through the immobilized Ni2+ 
ion. Pooled pellets from three litre expression cultures were resuspended in 
approximately 10 ml refolding buffer (100 mM sodium phosphate (pH 8.0), 10 
mM tris, 6 M guanidine-HCl, 10 mM imadazole).  Afterwards the suspension 
was subjected to sonication using a sonopuls ultrasound system and a TT13 
sonotrode (Bandelin)  with an output power of 150 W and a setting of 1 sec 
(on)/1 sec (off) for approximately 45 min. After sonication, the suspension was 
spun down at 32,500 x g for 30 min. (RT). The supernatant was immediately 
used for affinity chromatography. In the meanwhile, Ni-NTA was equilibrated 
with refolding buffer and then supernatant was mixed and coupled with the 
equilibrated Ni-NTA suspension. The mixture was slowly agitated for one hour 
at RT. After coupling the column was packed with Ni-NTA resin. Using an 
AKTA Prime system (GE Healthcare) the denatured protein was refolded on 
the column using a linear gradient to refolding buffe .  Next the protein was 
eluted with a linear gradient to elution buffer [100 mM sodium phosphate (pH 
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5.8), 10 mM tris, and 500 mM imidazole]. The purification protocol is given 
below in table 7. 
 
Table 7: Purification protocol for recombinant shPrP 
 
Step Buffer Time  
(min) 
Flow rate  
(ml/min) 
Wash G 16 2.5 
Equilibrate G 40 2.5 
Gradient G→B 100 0.5 
Wash  B 56 2.5 
Elute C 32 2.5 
Wash B 24 2.5 
   
    
After purification suitable fractions were pooled and dialyzed against 10 mM 
Tris (pH 8.0). The His-tag of the protein was removed by thrombin digestion for 
20-24 hours at RT. The applied thrombin concentration was 2 U per μmol PrP. 
The digest was stopped by adding 10 μl of benzamidin sepharose per unit 
thrombin. After adding the sepharose agitation was continued for two hours at 
RT. Afterwards the sepharose was filtered out and the protein solution was 
dialyzed three times against water at 4°C. Then, the protein was concentrated 
and stored at −80°C. 
 
3.2.2 Proteinase K Digestion 
All the samples were spun down at 25,000 x g for 20 minutes on the micro 
centrifuge at 22°C. The supernatant was discarded and the pellet was 
resuspended in 6 μl of 1 X PBS. Then 6 μl of ice cold 2X PK solution was 
added to give the end concentration of 0.5 μg/ml PK. After a brief vortexing 
step, the samples were placed immediately on the thermoshaker (750 rpm, 
37°C) for one hour. To stop the digest after one hour, 4 μl of 4 x LDS sample 
buffer was added to the digestion mixture. The samples were immediately 
heated at 96°C for 10 minutes. Later all the samples were spun down at 
25,000 x g for 10 seconds and loaded onto SDS gel for silver stain analysis. 
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3.2.3 SDS-Polyacrylamide-gel electrophoresis (SDS-PAGE) 
SDS PAGE was performed using a commercially available gels from Invitrogen 
(NuPAGE® Novex 4-12% Bis-Tris Midi Gels). 12 µl of sample (6 µl of reaction 
mix + 6 µl of 2x PK) was mixed with 4 μL of 4 x LDS sample buffer (Invitrogen) 
and heated at 96°C for ten minutes. 15 μL of the sample was then loaded to 
the individual wells of the SDS gel placed in a vertical electrophoresis tank 
(XCell4 SurelockTM Midi-Cell, Invitrogen) with 1X SDS running buffer (20 x 
running buffer, Invitrogen). 7 μl marker was also loaded to one well. 
Electrophoresis was carried out at 200 V for 35 minutes. 
 
3.2.4 Silver Staining 
Silver staining was carried out with a Pierce Silver Stain Kit from Thermo 
Fisher Scientific. The SDS gel was removed from the electrophoresis cassette 
and washed twice for 5 minutes in filtered Milipore water to remove the salts of 
the running buffer. Then the gel was incubated for 15 minutes in fixing solution 
made of 30% ethanol, 10% acetic acid and 70 % water. The fixing process 
was repeated once again for 15 minutes. Then the gel was washed twice for 5 
minutes each with 10% ethanol and with Milipore water. In the meanwhile the 
Sensitizer Working Solution was prepared (50 µL Sensitizer mixed with 25 mL 
water).The gel was incubated with the Sensitizer Working Solution for 1 
minute, followed by 2 washes with water for 1 minute each. The Stain Working 
Solution (0.5mL Enhancer mixed with 25 mL Stain) was prepared and the gel 
was incubated for 30 minutes. The Developer Working Solution (0.5 mL 
Enhancer with 25 mL Developer) was prepared. The gel was washed with 
ultrapure water twice for 20 seconds at each wash. The gel was then 
incubated with the Developer Working Solution 2 to 3 minutes until the bands 
appeared. Immediately after the bands appeared 5% acetic acid was added 
and incubated for 10 minutes. 
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3.2.5 Prion Decontamination 
Table 8: Prion Decontamination procedures 
 
Type of Object 
 
Decontamination 
 
Surface (e.g. lab furnitures), 
Plastic ware (e.g. dishes, beakers) 
1 M NaOH (≥ 1 h), cleaning with 1 % 
(v/v) LpHse  
Solid waste (e.g. gloves, tissue paper) 
and animal cages 
Autoclaving at 134°C  
Body parts of prion inoculated animals Incubated in 1 M NaOH/0.2% (w/v) 
SDS (≥ 1 h) and autoclaved at 134°C 
Metal-objects and glassware Incubated in 1 M NaOH/0.2% (w/v) 
SDS (≥ 1 h) and autoclaved at 134°C
Shear-generators (1) Incubation in 1 M NaOH/0.2% 
(w/v)  SDS  for 1 h 
(2) Auroclaving at 121°C in 1 M 
NaOH/0.2% (w/v) SDS   
(3) Auroclaving at 121°C in 5% milk 
powder  
 
3.2.6 SSA Assay 
Selective Shearing Amplification (SSA) Array 
Till date, direct structural measurements of rec. PrP aggregates are prevented 
by the small quantities. Moreover, to further address the need for homogenous 
and seed specific rec. PrPres preparations, an instrument was designed and 
built in our group by Dr. Thorsten Lührs (HZI), which we called as “SSA Array”. 
The principle is based on the use of mechanical shear stress as a shearing 
mechanism. When the viscous fluid is confined in the gap between two rotating 
cylinders, homogenous shear fields can be generated that are proportional to 
the rotation frequency of the cylinder. Using custom-designed, induction-driven 
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dispersion tools (Heidolph, Silent Crusher S, tool 7F − Stator diameter (outer): 
7 mm, Rotor diameter: 3.9 mm, Slot width: 0.6 mm, Shaft length: 55 mm, 
Volume: 6.0 - 10.0 ml) as shear- generators, homogeneous and reproducible 
shear forces could be applied to arbitrary reaction volumes. With mechanical 
SSA, it was possible to test different parameters (e.g. different shearing 
conditions, cycle times, different seed and substrate concentrations, buffer 
compositions etc.) using several geometrical identical shear-generators 
running in parallel. To accomplish this, the SSA-array was built (Figure 8). (A) 
It consists of 28 slots for shear-generators which can run simultaneously in a 
temperature-controlled environment maintained by the attached water bath. 
Using computer controlled switching relays; every single device can be 
programmed separately for experiments using rotation frequencies ranging 
from 40 to 1,201. (B) Detailed view of seven dispersion tools in the SSA array. 
The reaction tube containing the desired volume was inserted onto the 
dispersion tool and then the whole assembly was sealed with a parafilm in a 
laminar-flow hood. Then it is inserted into the SSA array and processed at 
specified parameters. The rotation frequency of each unit is pre-set using the 
multimeter shown in (A). Using this array, reactions of different volumes can be 
processed which turned out to be a great advantage for making substantial 
amounts of labeled recombinant PrPres. (C) Shows the shear generator which 
can homogenize a reaction volume of 10 ml. The system comprises of a rotor 
of radius, r, rotating with a frequency, , inside a stator. The gap between the 
rotor and stator of height, h, is filled with a solvent of viscosity η. With these 
parameters the shear-rate, G, and the shear-force, can be calculated. Since 
shear force is proportional to the rotational frequency, it can be controlled with 
great precision and reproducibility. Bold arrows indicate local solvent velocity, 
and the white arrow indicates the direction of rotation. (D) Evolution of cycle 
time during the course of the reaction.  
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Preparation of Reaction Mixes  
Round 0 Reaction 
1) Preparation of 4X Reaction Buffer 
Composition of 50 ml of 4X Reaction Buffer  
10% SDS stock (stored at RT) 2 ml 
10% Triton X-100 stock (freshly prepared )  2 ml 
10 X PBS stock (stored at -80°C) 20 ml 
Milli-Q water 26 ml 
Filter through 0.2 µm membrane  
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2) Filtration of the Substrate 
Recombinant Hamster PrP (23-230) was spun down at 283,807 g for 30 
minutes at 4°C. The supernatant was carefully transferred and filtered with a 
100 kDa filter (PALL) by spinning at 5000 X g for 45 minutes. Later O.D was 
measured at 280 nm. In order to achieve the final concentration of 0.3 mg/ml, 
the protein solution was diluted with ice cold and filter sterilized (0.2 µm 
membrane) Milli-Q water and stored on ice. 
3) Dilution of the Seed 
10% (w/v) scrapie brain homogenate (ScBH) was thawed at 22°C under gentle 
agitation (Eppendorf Thermomixer comfort, 750 rpm). Then it was briefly 
spinned down at 25,000 x g on the micro-centrifuge and stored on ice. 
Simultaneously 100X N2 supplement was also thawed and stored on ice. For 
dilution of the seed, 1X N2 supplement was prepared in 1X reaction buffer. 
10% ScBH was diluted 1:50 into 1X N2 and vortexed for one minute and later 
stored on ice. 
4)  Preparation of the reaction mix  
For 10 ml reaction volume, following components are added in the specified 
order: 
Milli-Q water − Ice cold and filter sterilized (0.2 µm  
 
membrane)  
3.967 ml 
4X reaction buffer − Ice cold and filter sterilized  
 
sterilized (0.2 µm membrane)  
    2.5 ml 
ScBH seed diluted in 1X N2     0.2 ml  
Mix well by pipetting  
0.3 mg/ml of ice cold rec. Hamster PrP (23-230)  3.333 ml 
Total volume      10 ml 
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5)  Starting the reaction 
 
Once the reaction mix was prepared, shear generators (Heidolph, Silent 
Crusher S, tool 7F − Rotor radius: 1.95 mm, Slot width: 0.6 mm, Volume: 6.0 - 
10.0 ml, see Fig. 1.6C) were inserted into the reaction mix. The whole 
assembly was then allowed to warm to 37°C in the water bath for 20 min. Then 
one by one they were placed on the array and the processing was started: The 
processing frequency (rotation frequency of the rotor) was pre-set to specific 
values between 95 Hz and 1200 Hz If not indicated otherwise, the reactions 
were processed at 37°C for 5 seconds using a cycle time of 5 minutes. In order 
to trace the buildup of rec. PrPSc over time, samples of 250 μl each were 
collected at predefined time-points during the run, and stored at RT for later 
analysis. All collected kinetic samples were then analyzed at once by PK-
digestion and silver staining. 
 
Round 1 Reactions 
 
For serial propagation of rec. prion seeds, 1:50 dilution of the previous round 
product (round 0 reaction) as a seed was used. 
Round 1 reaction mix was prepared in the following order where the 
components are added in the specified order: 
Milli-Q water − Ice cold and filter sterilized (0.2 µm  
 
membrane)  
3.967 ml 
4X reaction buffer − Ice cold and filter sterilized  
 
sterilized (0.2 µm membrane)  
    2.5 ml 
Sample vol. from previous round     0.2 ml  
Mix well by pipetting  
0.3 mg/ml of ice cold rec. Hamster PrP (23-230)  3.333 ml 
Total volume      10 ml 
  Materials & Methods 
50 
 
Characterization of SSA Products 
 
3.2.7 Mass Spectrometry 
To distinguish between Sc237 and 263K Hamster prion strains, samples were 
analyzed by electrospray ionization mass spectrometry (ESI-MS). The 
measurements were carried out by Dr. Manfred Nimtz and Andrea Abrahamik 
(HZI, Braunschweig). A single 10 ml reaction was spun down at 283,807 g for 
30 minutes at RT. The pellet was resuspended in 100 µl of 1X reaction buffer. 
Later it was digested with 0.5 µg/ml proteinase K for one hour at 37°C. The 
digest was stopped by placing the sample immediately on the dry bath which 
was already set to 96°C for 10 minutes. Afterwards, sample with inactivated 
PK was spun down at 25,000 g for 10 minutes at RT. The supernatant was 
discarded and the pellet was recovered. In order to wash the pellet and to get 
rid of the detergents, it was resuspended in 200 μl of filter sterilized (0.2 μm 
membrane) Miili-Q water and again spun down at 25,000 g for 10 minutes. The 
washing step was repeated 3 times. Finally the pellet was further purified by 
methanol/chloroform extraction. The resulting pellet was inactivated in 50 µl of 
hexafluoroisopropanol (HFIP) and analyzed for electrospray ionization mass 
spectrometry 
 
3.2.8 Electron Microscopy 
For analysing rec. PrPres samples through transmission electron microscopy 
(TEM), aggregates from a 10 ml reaction were collected and digested with 
0.5 µg/ml PK for one hour at 37°C. All the brain derived samples (10% 
Sc237 and 263K infectious brain homogenate along with 10% Syrian 
hamster normal brain homogenate) were digested with two different PK 
concentrations – 50 µg/ml and 100 µg/ml. These and PK untreated samples 
were then settled onto carbon-coated butvar grids for 10 minutes.  Excess 
sample was removed and the grid was air-dried. The fibril-bearing grid was 
stained with 2% (w/v) uranyl acetate for few seconds. Images from randomly 
selected areas were captured on a film at 5,000 –25,000× magnification. 
 
  Materials & Methods 
51 
 
3.2.9 Solid state Nuclear Magnetic Resonance (ssNMR) Spectroscopy 
For solid-state experiments, pellets of Sc237 at three different frequencies – 
189 Hz, 378 Hz and 953 Hz and 263K at 378 Hz and 953 Hz were prepared 
using 13C/15N-labeled full length Syrian hamster PrP (23-230). A total of 60 
reactions of 10 ml volume corresponding to ~ 30 mg were pooled to make one 
ssNMR sample at the required frequency. Reactions at 953 Hz were 
processed for 2 hours at 37°C on the SSA array. Similarly, reactions 
corresponding to 378 Hz were processed for 6 hours and those running at 189 
Hz were completed at 9 hours. Afterwards, when the reaction was over, 
recombinant PrP aggregates were collected at 283,807 g and analyzed by 
ssNMR spectroscopy. 
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4 Results 
 
Prion diseases are associated with the conversion of the α-helix rich prion 
protein (PrPC) into a β-sheet-rich insoluble conformer (PrPSc) that is thought to 
be infectious. The mechanism for the PrPC → PrPSc conversion is still 
unknown, partly because of the limited knowledge of the structure of PrPSc. 
Many efforts have been made over the years to recapitulate PrPSc formation 
and prion propagation in vitro.  
The development of “protein misfolding cyclic amplification” (PMCA) allowed 
propagation of prion infectivity in vitro under cell free conditions. PMCA 
reactions involved successive rounds of incubation and sonication of either 
crude brain homogenates (Castilla et al., 2006) or purified brain derived PrPC 
and, some groups have even tried using bacterially expressed recombinant 
(rec.) PrP (Atarashi et al., 2007). However, in most of the labs including our 
own standard PMCA is rather hard to control. The delivery of vibrational 
energy to samples can vary substantially and unpredictably with tube position, 
probe age and water bath volume. Later, in the group of Byron Caughey, 
another method was established called a “Quaking Induced Conversion 
(QuIC)”. In this method, sonication was substituted by recurrent cycles of 
shaking and incubation (Atarashi et al., 2008). Using a thermoshaker, 
reactions of 100 µl were processed and converted to proteinase K (PK) 
resistant forms. This method was much more convenient and reproducible 
than PMCA. Thus, we adopted “QuIC” as a method of choice in order to 
generate prions using rec. PrP as a substrate. After thorough screening of all 
the reaction parameters (such as shaking conditions, detergent 
concentrations, incubation time and reaction temperature) we could finally 
amplify prions under in vitro conditions. However, we found that the yield of 
the standard reaction was < 5% and thus the quantity and the  quality were 
insufficient for carrying out structural studies. The QuIC reactions on the 
thermoshaker worked only in small volumes (≤100 µl). We tried to scale-up 
the reaction volume to 500 -1000 µl, but were unable to observe any 
detectable amplification of prions. Thus, in summary, the amplification of prion 
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protein using agitation by ultrasound or by shaking is volume dependent and 
the yields of protease resistant prion protein are hardly reproducible. 
Moreover, the drawback of all these methods is that the quantities of PrPSc 
generated are very small, precluding most structural studies. 
In this context, an initiative was taken in our group by developing a novel 
method called “Selective shearing amplification (SSA)”. Using a custom-
designed device (See Methods, 3.2.6) we can apply homogeneous and 
reproducible shear forces to arbitrary reaction volumes.  With the help of SSA, 
we tried to mimic the PrPC → PrPSc conversion in vitro. PrPSc seed from crude 
brain extracts of scrapie-infected animals was used to induce conversion of 
rec. PrPC into a PK resistant isoform, PrPres. Newly formed PrPres can then be 
routinely identified by PK digestion followed by silver stained SDS gel 
electrophoresis. The fragments generated by PK-digestion were ~ 10-12 kDa 
along with the 17 kDa product (6-7 kDa smaller than the rec. PrPC) which is 
characteristic of the PK resistant core of PrPSc, PrP27-30 (Oesch et al., 1985; 
Hope et al., 1986).   
In the current study, an attempt was made to develop a standardized method 
for rec. prion amplification under in vitro conditions using SSA (Figure 9). All 
the key parameters that could influence the rec. PrPres amplification were 
tested systematically. The optimization of the main conditions was essential in 
order to establish a reliable method with optimal settings that support specific 
PrPSc-seeded in vitro conversion of rec. PrPC. The optimized conditions were 
then adapted to produce the homogenous and reproducible rec. PrPres 
sample from two different hamster prion strains, Sc237 and 263K. These rec. 
PrPres preparations were further characterized by (i) SSA, (ii) Negative 
staining electron microscopy, (iii) Mass spectrometry and (iv) NMR 
spectroscopy. Figure 9 demonstrates the experimental scheme designed for 
this project. 
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Figure 9: Experimental Layout 
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4.1 Conditions for Strain Selective rec. PrPres Amplification 
Development of SSA for conversion of rec. PrPC to PrPres requires detailed 
study and optimization of all the essential parameters that could influence the 
overall amplification rate. These include (i) the rec. PrPC concentration 
(substrate), (ii) the PrPSc concentration (seed), (iii) Protease treatment of the 
infectious prion seed (for purification of PrP27-30, the protease-resistant core of 
PrPSc), (iv) the concentration of detergents in the reaction buffer, (v) the 
processing conditions and (vi) the minimum ‘seed’ requirement for 
amplification upon serial dilution.  Initially it was necessary to determine to 
what extent these individual parameters influenced the degree of amplification 
achieved. This section focused on the development and optimization of SSA, 
through systematically testing all the above mentioned conditions which 
perceived to affect PrPSc seeded in vitro conversion of rec. PrPC. 
We started our investigation by following the conditions mentioned in the 
“QuIC” protocol published by the group of Byron Caughey (Atarashi et al., 
2008). However, instead of thermoshaker as a means of agitation, we applied 
homogenous shear forces by using 10 ml shear generators, for rec. prion 
protein conversion and amplification. Making “QuIC” method as the basis of 
our work, we started optimizing conditions by SSA.  
 
As a starting experiment, we tried to generate PK resistant forms using 
hamster Sc237 brain homogenate as a seed and rec. syrian hamster prion 
protein, shPrP (23-231), as a substrate. We scanned the entire accessible 
rotation frequency range (75 Hz – 1200 Hz) using a logarithmic scale with 
increments of 26%. The reactions were carried out in a volume of 10 ml using 
a shear generator. A total of 14 shear generators each running at a specified 
frequency or shear force (7F-Heidolph) were used. The seed and the 
substrate concentration along with the reaction buffer constituents were 
initially the same as used in the QuIC protocol  (Atarashi et al., 2008). Each 
10 ml reaction of 100 µg/ml bacterially expressed hamster rec. PrPC (residues 
23-231) was seeded with 1/2500 dilution of a 10% Sc237 brain extract. The 
reaction buffer contained a combination of 0.1% of an anionic detergent such 
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as SDS and 0.1% of a non-ionic detergent such as Trion X-100. All the 
reactions were processed in parallel for 5 seconds every 5 minutes using the 
SSA-array (See Methods, Fig. 8) for 22 hours at 37°C. Afterwards, the PrP 
aggregates were collected by centrifugation, digested by PK and analysed by 
silver-stained SDS-gel electrophoresis. Silver staining offers the advantage to 
observe all peptides that are generated, whereas western blotting detects only 
the specific epitopes of the monoclonal antibody. We observed a strong band 
at 17 kDa (characteristic of the PK resistant core of PrPSc, PrP27-30) in all the 
processed reactions other than 75 Hz and 1200 Hz (Fig.10). We assumed 
that at 75 Hz because of less efficient shearing, we were not able to generate 
any detectable PK resistant form. However, at 1200 Hz the shear force might 
be too strong for the prion protein conversion and amplification.  We also 
observed a strong 12 kDa band in all of the processed reactions which was 
also reported in the “QuIC” assay  (Atarashi et al., 2008). Moreover, in the 
non-processed control (lane 1), we did not observed any amplification at all. 
This provided the evidence that shear force can successfully substitute 
sonication and shaking as a means of agitation. Using the shear generators 
we can scale-up the reaction volume upto 200 mL which cannot be fulfilled by 
any of the published method so far. Notably, at frequencies of 150 Hz, 378 
Hz, and 756 Hz, the 17 kDa band was more intense than other frequencies. 
These observations provide some initial evidence for the co-existence of 
multiple PrPSc conformations within a single prion strain. Thus, we concluded 
that Sc237 might possibly contain multiple PrPSc conformations, which can 
individually be selected by SSA based on their characteristic molecular 
resistance against seed fragmentation. Overall, with this experiment we 
demonstrated the applicability of SSA for strain selective conformational 
conversion and amplification of recombinant PrP.  
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4.1.1 Influence of rec. PrPC (Substrate) Concentration on the 
Conversion     Behavior 
With the initial success in achieving conversion and amplification of rec. prion 
protein using SSA, we then focussed on optimizing and validating individual 
parameter that could influence the degree of amplification. We used Sc237 
hamster prion strain as a seed and 756 Hz processing frequency for carrying 
out the optimization study. The first parameter that we checked was the rec. 
PrPC (substrate) concentration.  
We tested three different concentrations (12.5, 25 and 50 µg/ml) of rec. PrPC 
along with the standard concentration of 100 µg/ml which was used in the 
initial experiment in Fig. 10. Other parameters which include (i) the 
concentration of PrPSc as a seed (1/2500 dilution of a 10% Sc237), (ii) the 
processing conditions (5 sec. in every 5 min.), and (iii) the reaction buffer 
constituents (0.1% of both SDS and Triton X-100) were kept constant as in 
Fig 10.  All the reactions were processed at 756 Hz in the SSA array using a 
10 ml volume shear generators where each generator was running with a 
specified PrPC concentration. In order to trace the kinetic build-up of the rec. 
PrPres formed, we collected 250 µl of sample from individual reaction mixes at 
the indicated time points and stored at RT.  After 22 hours when the reaction 
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was over, all the aliquots were spun down at 25,000 x g for 20 minutes. The 
resulting pellets were resuspended in 6 µl of PBS containing 0.1% of both 
SDS and Triton X-100. The samples were digested by 0.5 µg/ml PK for 1 hr. 
at 37ºC and later analyzed by silver stained gel electrophoresis. Fig. 11 shows 
the effect of modifying substrate concentration on the rate of rec. PrPres 
amplification. We obtained the most intense rec. PrPres bands (17 kDa) at the 
substrate concentration of 50 – 100 µg/ml. We traced the amplification rate of 
all the reactions and observed that at half the substrate concentration i.e. 50 
µg/ml than the “QuIC” assay (100 µg/ml), the same intensity of the 17 kDa 
(reminiscent to PK resistant core of PrPSc) band was achieved in just 6 hours. 
At 22 hr. the reaction was already over-processed as can be seen by the 
decline in the intensity of the 17 kDa product. Consistent with the previous 
findings with “QuIC” reactions, we also observed the smaller 10 kDa bands 
which were also most intense at 50 and 100 µg/ml of substrate concentration. 
At lower substrate concentrations (12.5 and 25 µg/ml), there was virtually no 
amplification at all as indicated by the absence of 17 kDa product. We only 
observed the undigested 23 kDa rec. PrPC band which was subsequently lost 
over the time. Thus, for the further study we selected 50 µg/ml of substrate 
concentration as the optimal condition.  
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4.1.2 PrPSc (Seed) Concentration and the Effect of Protease Digestion 
of Seeds on the Conversion Behavior 
After optimizing the substrate concentration, the next parameter tested was the 
minimum concentration of PrPSc (seed) required for amplifying rec. PrPres. With 
the same experiment, we further tried to investigate the impact of protease 
treatment of seeds on the amplification rate. This was an attempt made 
towards purifying the seed for structural studies.  
 
For conducting the experiment, 10% Sc237 brain homogenate as a seed was 
tested at five different dilutions (1/10, 1/25, 1/50, 1/100 and 1/200) using a 
substrate concentration of 50 µg/ml. After dilution, the seed was digested with 
5 µg/ml proteinase K (PK) for 1 hr. The PK was inactivated by heating of the 
seed at 95ºC for 10 minutes. Later, using the seeds that were either treated 
(Fig. 12 B) or not treated with PK (Fig. 12 A), the optimal concentration of 
PrPSc was determined. The processing conditions (5 seconds every 5 minutes) 
and the reaction buffer constituents (0.1% of SDS and Triton X-100) were kept 
constant. All the reactions were processed at 756 Hz frequency in the SSA 
array using the 10 ml shear generators. In order to trace the amplification rate 
of the reactions, 250 µl of samples were collected at indicated time points and 
stored at RT for later analysis by silver stained SDS gel electrophoresis. 
 
Fig. 12 demonstrates the optimal PrPSc concentration required for rec. PrPC 
conversion and amplification along with the effect of protease treatment of 
PrPSc. On comparing Fig. 12 A (undigested seed) with Fig. 12 B (seed with PK 
digestion), overall we observed higher seeding potency of the samples that 
were not treated with PK (Fig. 12 A), if focused on the 17 kDa band formation. 
From 1/50 dilution onwards, the effect of proteases can be seen prominently 
as there was a drastic decline in the rate of amplification if the seed was pre-
treated with PK (Fig. 12 B). At 1/50 dilution, undigested seeds could easily 
amplify rec. PrPres in 6 hours as indicated by the presence of a strong 17 kDa 
band (Fig. 12 A). Moreover, the reaction product once formed is quiet stable 
until 22 hour. To the contrary, at the same dilution, PK digested seeds showed 
a very faint band only after 9 hours which vanishes completely over 22 hours. 
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Overall, if we compare the 17 kDa band formation under both the conditions, it 
becomes clear that (i) undigested PrPSc is more efficient seed than PK 
digested PrPSc and (ii) 1/50 is the optimal seed concentration required for 
efficient conversion of rec. PrPC.  Thus, the quantity and the quality of the seed 
substantially influence the conversion behavior. 
 
 
 
4.1.3 Concentration of Detergents in the Reaction Buffer 
After optimizing the concentration of seed (Fig. 12) and the substrate (Fig 
11), the next condition tested was the concentration of both anionic detergent 
such as SDS and non-ionic detergent such as Trion X-100 in the reaction 
buffer. Since SDS has been found to induce structural conversion of α-
helices to β-sheets and  aggregation of hamster rec. PrP (residues 23–231) 
(Xiong et al., 2001), it was necessary to determine the optimum 
concentration of detergents in the reaction buffer. 
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Fig. 13 summarises the effect of varying concentrations of both SDS and 
Triton X-100 on rec. PrPres amplification. The standard concentration of both 
the detergents used in “QuIC” assay was 0.1%. We tested different 
concentrations of SDS and Triton X-100 (0.09, 0.1 – standard, 0.11, 0.12, 
0.13 and 0.14%) using the optimal concentration of seed (1/50 of 10% Sc237 
brain homogenate) and the rec. PrPC as a substrate (50 µg/ml). The 
processing conditions were kept constant like previously (5 sec. in every 5 
min).  All the reactions were running at the rotational frequency of 756 Hz 
Amplification rates of the reactions were traced by collecting 250 µl of 
samples at indicated time points. All the samples were stored at RT and later 
digested with 0.5 µg/ml PK and analysed by silver staining.  Fig. 13 A 
showed the effect of different concentrations of SDS using the standard 
concentration (0.1%) of Triton X-100. We obtained the most intense 17 kDa 
band (corresponding to the PK resistant core of PrPSc, PrP27-30) at the 
concentration of 0.1%. Notably, the presence of SDS had such a major effect 
on the PrPres amplification, that if we increase the concentration just by 
0.01%, the amplification rate dropped drastically.  Fig. 13 B showed the effect 
of different concentrations of Triton X-100 using the standard concentration 
(0.1%) of SDS. We again observed the maximum amplification at 0.1% Triton 
X-100 concentration as indicated by the 17 kDa band. However, on 
decreasing the concentration by just 0.01%, the amplification was hindered 
completely. Overall, these findings were consistent with the “QuIC” assay 
where the optimal concentration of both detergents was 0.1% . In both the 
cases, we also observed the 23 kDa undigested rec. PrPC band along with 
the smaller 10 kDa C-terminal fragment of the prion protein. Another 
important observation was the fact that at 0.1% SDS and 0.1% Triton X-100, 
reaction was completed after 6 hours using SSA. This is consistent with all 
the previous observations made during the optimization of seed and 
substrate concentration (Fig.11 and Fig 12). Thus, there was a high degree 
of reproducibility in PrPres amplification with SSA. 
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4.1.4 The Effect of Processing Conditions on Strain Selective 
Amplification of Hamster Prions 
We further investigated the influence of processing conditions on detecting 
strain specific differences between Sc237 and 263K hamster prions using rec. 
PrPC as a substrate. We used all the optimized conditions, i.e. 50 µg/ml 
substrate concentration, 1/50 dilution of 10% Sc237 or 263K hamster prion as 
a seed and the reaction buffer containing 0.1% of SDS and Triton X-100, for 
the current investigation. The constant processing of 5 sec. in every 5 min 
was substituted with incremental processing where 5 seconds processing 
time remains constant but the cycle time increases exponentially (See 
Methods Fig 8D). 
 
Fig. 14 summarises the differences between Sc237 and 263K prions under 
the influence of incremental processing. For both Sc237 and 263K prion 
strains, we observed a characteristic pattern of bands at 23, 17 and 10 kDa. 
As explained previously, most notable was the formation of 17 kDa band on 
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the gel.  The amplification rate of the reactions was monitored up to 12 hours. 
250 µl of samples were collected at indicated time points and later digested by 
0.5 µg/ml PK and analyzed by silver staining. After 12 hours, multiple 
amplification optima were observed for Sc237. We assumed at least three 
optima to be present at processing frequencies of 1200 Hz, 378 Hz and 
possibly around 189 Hz (Fig. 14 A). At 1200 Hz, we noticed the fastest 
amplification rate as the reaction was completed in 4 hours. However, the 
other optima were not as clear since the amplification was observed over the 
wide range of processing frequencies. Notably, when the same experiment 
was performed using the 263K strain (Fig. 14 B), only one optimum near the 
maximal processing frequency (1200 Hz) was observed. Unlike Sc237, the 
maximum amplification was obtained only at one rotational frequency of 1200 
Hz where the reaction was completed in 4 hours. At lower frequencies, there 
was virtually no amplification at all.  
 
 
 
Except for the seed, the two reactions were identical in terms of their 
composition. For further proof, we then conducted a non-seeded reaction, 
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using the same processing tools as before, where the seed was replaced with 
the normal brain homogenate from the healthy hamster (Fig. 14 C). All the 
other conditions were same as seeded reactions. Evidently, we did not 
observe any detectable formation of PrPres on the silver stained gel, not even 
at 1200 Hz. This proved that PrPres formation is not induced shearing 
mechanisms and that the processing tools can be fully decontaminated for the 
process. Thus, from the mixed initial seed population, homogenous shearing 
appears to select the optimally fragmented population and suppresses all 
others.  
 
4.1.5 The Minimum ‘Seed’ Requirement for Amplification upon Serial 
Dilution 
All the key parameters that could influence the conversion and the 
amplification behaviour of rec. PrPres have now been optimized. However, we 
still needed to figure out the optimal dilution of the initial round product into the 
subsequent round for efficient serial propagation of prions seeds.  Based on 
our previous observations, we chose to run a single reaction at 756 Hz for 12 
hours (Fig.11 and Fig.12). The resulting reaction product was added as a 
seed into fresh rec. PrPC at four different (1/25, 1/50, 1/100 and 1/250) 
dilutions and the next round of propagation was initiated.  
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Fig. 15 demonstrated the most intense 17 kDa bands at 1/25 dilution (4 h. 
product) and at 1/50 dilution (6 h. product). The intensity of 6 h. product at 
1/100 is slightly less than 1/50. Thus, between 1/25 and 1/50, we decided to 
choose for the higher dilution of the seed i.e. 1/50 for serial propagation of 
hamster prions. 
 
 
4.2 Serial Propagation of Hamster Sc237 and 263K Prions  
We have thus far optimized all the required conditions for amplification of 
hamster brain derived prions using recombinant PrPC as a substrate. In 
summary, the optimized conditions are: (i) Substrate concentration – 50 µg/ml 
(ii) Seed concentration – 1/50 of 10% Sc237 or 263K brain homogenate, (iii) 
Reaction buffer – 0.1% SDS and 0.1% Triton X-100, (iv) Processing 
conditions –  incremental processing and (v) Dilution of previous round seed 
for serial propagation – 1/50. We adapted all the above mentioned optimized 
parameters for in vitro serial propagation of Sc237 and 263K hamster prions.   
 
In order to dilute out all of the original PrP27–30 associated infectivity, we 
performed ten serial rounds of reactions over the entire range of rotational 
frequency (95 – 1200 Hz) using both Sc237 (Fig. 16 A) and 263K (Fig. 16 B) 
hamster strains. We used all the optimized conditions for serial propagation 
where the initial round product was diluted 1/50 into the subsequent round.  
The round 0 reactions for all the rotational frequencies were processed for 9 
hours. We selected 9 hours because the reactions at higher frequencies are 
not overly processed at the same time providing the opportunity for lower 
frequency reactions to amplify as well. However, for subsequent rounds we 
traced the amplification rate for all the reactions until it was stabilized. For 
demonstration, we showed the amplification rate of three frequencies – 189, 
378 and 953 Hz for both Sc237 (Fig. 16 C) and 263K (Fig. 16 D) prions.   
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From each round, at the indicated time points we collected 250 µl of sample 
for silver stain analysis and an additional 200 µl as a seed. Later on the basis 
of silver stain result, we used the product which showed the maximum yield 
as a seed for the next round. This approach was followed till round 7 for 
Sc237 and round 5 for 263K. Once the amplification rate was stabilized, the 
reactions of the following rounds were processed for the specific optimized 
time point. By doing this, we tried to avoid over-processing of the samples 
which could negatively influence on the overall quality of the reaction product 
for later structural analysis by NMR. After round 10, all the samples were 
shock frozen in liquid nitrogen and stored at -80ºC in aliquots of 500 µl for 
future use.  
 
4.3 Characterization of in vitro Propagated rec. PrP 
Aggregates 
Once the serial propagation of both Sc237 and 263K has been successfully 
achieved, the next objective was to characterize these in vitro propagated rec. 
PrP aggregates by (i) SSA to confirm in vitro PrPres conformational selection 
(ii) negative staining electron microscopy to detect morphological differences, 
(iii) mass spectrometry to identify major proteinase K (PK) resistant peptides, 
and (iv) solid state NMR spectroscopy to identify specific conformational 
differences at atomic resolution. Since Sc237 amplified well over a broad 
range of processing frequencies and showed multiple optima, we selected 
three frequencies − 189, 378 and 953 Hz for structural characterization. 
However, for 263K, we selected only two frequencies − 378 and 953 Hz as we 
observed only one optima at the maximal processing frequency.   
 
4.3.1 Characterization by SSA 
Splitting Experiment – Sc237 (953 Hz) 
 
We next explored the potential of SSA for selecting rec. PrPres conformation in 
vitro. For testing this, we used the serially propagated Sc237 and 263K 
samples which were frozen at -80ºC after round 10. After thawing the seed, 
  Results 
68 
 
we typically performed five to six serial rounds at 37ºC in order to activate the 
seed and then tested for rec. PrPres conformational selection by splitting the 
resulting reaction mix for processing across the entire shear force range on 
SSA array. 
 
(Fig. 17 A) demonstrated serial propagation of rec. Sc237 – 953 Hz seed up 
to round 26 which clearly proves that rec. PrPres generated by SSA can be 
propagated indefinitely.  
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After thawing the round 10 Sc237 seed at 953 Hz, it was serially propagated 
for additional 26 rounds following the same approach as in Fig 4.2. This was 
done in order to overcome the effects of freeze-thawing the sample and also 
to purify the seed for in vitro conformational selection. On splitting the round 
26 rec. Sc237- 953 Hz product (corresponding to 2.7 x 10-46 dilution relative to 
the initial seed), we clearly observed an amplification optimum at 953 Hz 
frequency and all other optima were relatively suppressed (Fig. 17 B).  At 
lower frequencies there was no amplification at all. The first detectable 17 kDa 
band appeared at 238 Hz after 15 hours. As the frequency increases the lag 
time of prion amplification decreases. Notably at 953 Hz, the reaction was 
completed in the shortest period of time of four hours (as indicated by the 
formation of the intense 17 kDa band) which at 1200 Hz was delayed to six 
hours. Thus we concluded that selective shearing is capable of purifying 
individual seed populations from PrPSc conformational mixtures. 
 
 
Splitting Experiment – 263K (953 Hz) 
 
For the proof of principle, we next repeated the same splitting experiment but 
with 263K hamster prion strain (Fig. 18). After round 10 we serially 
propagated the rec. 263K – 953 Hz seed for additional 40 rounds 
(corresponding to 4.4 x 10-70 dilution relative to the initial seed) and then split 
the resulting reaction mix. We observed the same behavior as with Sc237. 
PrPres amplification was observed only at ≥953 Hz processing, and all other 
optima were effectively lost. At 1200 Hz the reaction was completed in the 
shortest time of 2 hours (as indicated by the formation of the intense 17 kDa 
band) which was not observed at any other frequency. Thus, we clearly 
demonstrated that SSA can select PrPres conformations in vitro.  
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Splitting Experiment – Sc238 (378 Hz) 
 
We next tried to perform the splitting experiment with rec. Sc237 – 378 Hz 
seed corresponding to 43rd serial in vitro passage (Fig 19). At frequencies 
≤150 Hz there was no amplification at all. From 189 Hz onwards, we observed 
a strong 17 kDa band appearing at 22 hours. This demonstrates that the 
specific seeding activity of rec. PrPres seeds is dependent on the particle size 
of the aggregates, which is controlled by the fragmentation processes. In 
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general, as shown by the electron micrographs (Sim and Caughey, 2009) rec. 
PrPres are large sized aggregates which on selective shearing will amplify on a 
broader shear force range on SSA array. Thus we hypothesized that SSA has 
the potential to select differentially structured rec. seeds based on their 
specific mechanical fragmentability.  
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4.3.2 Characterization by Negative Staining Transmission Electron 
Microscopy (TEM) 
To study the morphological differences between in vitro propagated Sc237 
and 263K aggregates, the rec. PrPres samples were examined with 
transmission electron microscopy (TEM). In the brain of the scrapie infected 
animal, PrPres is often found as diffuse amorphous deposits which 
intermittently arranges itself into fibrils and extracellular plaques (Sim and 
Caughey, 2009). Merz et al. isolated scrapie associated fibrils (SAF) which 
are consistently found in TSE affected humans and animals and described 
distinct filaments within these fibrils (Merz et al., 1981). In 1983, Prusiner et al. 
described another form of scrapie fibrils, termed as prion rods, where the 
clear substructure was somewhat missing and distinct filaments were often 
hard to characterize  (Prusiner et al., 1983). 
 
In this study, we used negative staining TEM to compare rec. PrPres fibrils 
from both Sc237 and 263K hamster prion strains which are generated by 
SSA. Additionally, we also tried to obtain the morphological information about 
the brain derived infectious prion seed from both Sc237 and 263K prions. 
 
Serially propagated rec. PrPres samples from Sc237 (corresponding to − 189, 
378 and 953 Hz) and rec. 263K (378 and 953 Hz) were treated with 0.5 µg/ml 
PK at 37°C for one hour. All the brain derived infectious prion samples (10% 
Sc237 and 263K brain derived seed and with 10% Syrian hamster normal 
brain homogenate) were digested with two different PK concentrations – 50 
µg/ml and 100 µg/ml. All the samples were then settled onto carbon-coated 
butvar grids for 10 minutes, stained with Uranyl acetate for few seconds and 
then analysed by TEM.  
 
Fig. 20 showed electron micrographs of rec. Sc237 and 263K aggregates. at 
At 953 Hz Sc237 contained primarily matted clumps of fibrils and appeared 
more like prion rods published by Prusiner (Prusiner et al., 1983). They 
appeared to be different from 263K aggregates at the same frequency. The 
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263K fibrils (953 Hz) looked well defined with individual proto-filaments being 
visible and the morphological specificities were distinct.  Bars designate 200 
nm.  This strongly indicated that Sc237 differ substantially from 263K strain.  
 
In general at 378 Hz, 263K fibrils looked much cleaner and defined than 
Sc237 and the details of fibril morphology were more readily observed. 
However, on comparing the 263K fibrils at 378 and 953 Hz we could not 
observe any consistent ultrastructural differences and they looked almost 
similar. This is consistent with  the silver stained results (Fig. 14 B) that 263K 
consisted of only one detectable PrPres population at frequency ≥ 953 Hz. 
Notably, on comparing Sc237 at 378 and 953 Hz we observed marked 
diffrences between the two. In Sc237 at 378 Hz, individual fibrils were visible, 
though they were without any definition and the edges were completely 
blurred.  
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At 189 Hz Sc237 revealed thick overlapping fibre bundles and overall the 
morphology looked different from Sc237 at 378 and 953 Hz. Each fibril 
consisted of individual proto-filaments that appear to be helically wound 
around each other. Individual proto-filaments have a diameter of 1.5 –1.9 nm 
and appear equally spaced by approx. 3.5 nm. Bars designate 200 nm. 
 
On comparing TEM micrographs of the infectious brain derived Sc237 and 
263K prion seed, we observed clear morphological differences between the 
two (Figure 21). 
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Sc237 samples showed straight, very long and unbranched fibrils 
composed of either a single filament, or paired filaments twisted together 
with irregular periodicity (Fig. 21 A-B). The filaments were typically 7–12 nm 
in diameter and up to several µm in length. On the contrary, when 263K 
was examined under the electron microscope, we observed relatively low 
abundance of fibrils in comparison to Sc237 (Fig. 21 C). However, beaded 
substructures could be observed along the axis of proto filaments which 
were absent in Sc237. Similar beads have been described for SAF, and it 
has been speculated that they might represent subunits of the fibrils (Merz 
et al. 1981).  Notably, in the normal brain homogenate (NBH) from syrian 
hamster (Fig. 21D), we could not observe any fibrils. We just observed 
some membranes and vesicles, indicating that fibril formation is the 
characteristic feature of prions.  
 
 
4.3.3 Characterization by Electrospray Ionization Mass Spectrometry 
(ESI-MS) 
Detailed mass spectrometric analysis of Sc237 proteinase K (PK) resistant 
fragments was carried out by electrospray ionization mass spectrometry (ESI-
MS). The serially propagated Sc237 samples corresponding to 189, 378 and 
953 Hz processing frequencies were digested by 0.5 µg/ml PK for one hour. 
Following methanol/chloroform precipitation and inactivation of prions by 
hexafluoroisopropanol, the samples were analyzed by ESI-MS.  
 
The results revealed predominant species at masses of 10967.1, 12016.5, 
13448.3, 16094.4 and 19716.2 Da respectively (Fig. 22). Moreover, we 
observed that in all three frequencies of Sc237 (189, 378 and 953 Hz), the 
masses were rather same and we could not observe any characteristic 
changes in terms of their PK resistant mass fragments. However, the sizes of 
these PK-resistant fragments correlate remarkably well with the structured 
core region of the prion protein.  Thus we concluded that mass spectrometry 
is not the potential method for observing prion strain specific differences.  
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4.3.4 Initial Characterization of Selectively Amplified Recombinant 
PrPres by Solid State NMR 
We next prepared uniformly [15N] - labelled and [13C/15N] - labelled 
recombinant prions from Sc237 at three different frequencies – 189 Hz, 378 
and 953 Hz and from 263K at 378Hz and 953 Hz rotational frequencies.  
In order to obtain a substantial yield of isotopically labelled recombinant 
Sc237 and 263K prions, we first activated the amplified frozen round 10 seeds 
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by serial propagation using the unlabelled rec. PrPC as a substrate. Once 
activated, we split the resulting reaction mix equally to seed 12 reactions 
containing the 15N or 13C/15N shPrP (23-230), which were then processed 
under the identical conditions (Fig. 23). 
 
 
 
Fig. 23 shows the analytical PK digestion pattern of the obtained products, 
which is identically propagated over several rounds of serial reactions. 
Moreover, the yield appears to be rather uniform for all 12 reactions indicating 
a uniform behaviour of all the utilized processing tools. 
With the above mentioned approach (Fig. 23), we performed around 40-50 
serial propagation rounds for both Sc237 (189, 378 and 953 Hz) and 263K 
(378 and 953 Hz) prion strains and generated ~150-170 mg of unlabelled and 
isotope labelled sample. 
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Table 9 summarises the total amount of recombinant Sc237 and 263K prions 
prepared for this project. Overall, approx. 30 mg of 13C/15N and 60-70 mg of 
15N and unlabelled rec. Sc237 and 263K prions were prepared. 
Table 9: Summary of total amount of rec. Sc237 and 263K Prions prepared 
Hamster 
Strain 
Frequenc
y 
 (Hz.) 
No. of rounds 
required for 
seed activation 
15N labelled 
sample 
13C/15N 
labelled 
sample 
1H sample Total 
yield  
 
Sc237 
 
189 Hz. 
 
R11 – R19 
 
69 mg 
(R25 – R36) 
 
30 mg 
(R20 – R24) 
 
72 mg 
(R36 – R47)  
 
171 mg 
 378 Hz. R11 – R13 72 mg
(R14 – R2 
31 mg
(R29 – R33) 
60 mg 
(R34 – R43) 
163 mg 
 953 Hz. R11 – R15 63 mg
(R16 – R24) 
35 mg
(R27 – R31) 
61 mg 
(R32– R40) 
159 mg 
 
263K 
 
378 Hz. 
 
R11 – R14 
 
59 mg 
(R15 – R23) 
 
31 mg 
(R24 – R28) 
 
61 mg 
(R29 – R38) 
 
151 mg 
 953 Hz. R11 – R15 64 mg
(R16 – R24) 
33 mg
(R27 – R31) 
59 mg 
(R32– R40) 
156 mg 
 
Total 
800 mg 
 
 
In order to investigate the structural properties of the selectively amplified 
recombinant PrPres (Table 9), we next performed a series of solid state NMR 
experiments. For the analysis, about 15 mg of the individual reaction products 
were filled into 3.2 mm zirconium rotors. All NMR experiments were 
performed on a 14.1 T Bruker Avance III NMR spectrometer equipped with a 
triple resonance ssNMR probe using spinning frequencies of 10 kHz or of 13 
kHz, respectively. 
Figure 24 show the 2D [13C,13C] DARR spectra of the 953 Hz amplification 
products derived from 263K prions (Fig. 24A) and Sc237 prions (Fig. 24B). 
The DARR mixing time was 250 ms, which allows to observe cross-peaks of 
covalently linked 13C-atoms, and also cross peaks corresponding to pairs of 
13C-atoms that are spatially separated by less than 5 Å. Thus, these spectra 
provide direct evidence of the tertiary structures contained in the individual 
reaction products. The 263K-953 reaction product displays an overall peak 
pattern that would be expected for a highly ordered, very well defined proteins 
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tertiary structure. In contrast, the Sc237-953 sample displays a much less 
defined peak pattern, which is indicative of an ordered 3D structure that is 
overall less well defined. When individual parts of the two spectra are 
compared, several substantial differences in the tertiary structure become 
immediately evident: (i) in the region marked ‘a’, the spectral range where 
amino acid side chains of ASP- and GLU-  are observed. While 263K-953 
displays a well-defined pattern that corresponds to at least three ordered 
negatively charged side chains, the same spectral region of Sc237-953 lacks 
these peaks, and only weak resonances are observed. This indicates that 
263K-953 prions likely contain three salt bridges that form an integral and 
characteristic part of their 3D structure. (ii) the region marked ‘b’ contains the 
spectral range that contains the  C/C2 correlations of threonine side chains. 
For 263K-953, a characteristic peak pattern is observerd indication that 
numerous threonine amino acids are involved in structure formation. Also in 
Sc237-953 threonine side-chains are involved in structure formation, however, 
the overall pattern is distinct from 263k-953, and several cross-peaks are 
clearly absent from the Sc237-953 spectrum (see arrow-heads). Thus, the 
3D-structures of Sc237 and 263K appear to be distinct with respect to 
threonines. (iii) The spectra region that contains the resonances of isoleucine 
side chains (marked ‘c’) indicated that all these four contained amino acids of 
this type in the PrP sequence are ordered in Sc237 and in 263K. However, 
263K appears to contain two distinct close contacts between methyl groups of 
ILE and VAL, and of ILE and THR, respectively (see arrow heads). Thus, 
there appears to be high structural order around the isoleucines of 263K. (iv) 
The spectral region that contains medium-range and long-range contacts 
between the C-atoms of threonine side chains and side-chain-methylene 
groups of other amino acids (region ‘d’) are also characteristic and distinct 
btween the two recombinant prion amplification products.  
In summary of these first 2D-ssNMR [13C,13C]-spectra we have to conlude that 
the reaction products that were obtained from brain derived Sc237 prions, and 
from 263K prions, respectively, contain readily distinguishable tertiary 
structures. This suggest that these two prion strains are non-identical.  
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In order to obtain further insight into these prion structrues, we then asked 
whether these two recombinant reaction products can also be identified from 
their peptide backbone conformation. We thus recorded 2D-[15N,13C] 
correlation spectra, where one cross-peak is expected per ordered amino-acid 
residue (Fig. 25).  
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For 263K-953, we observed a very well-defined set of at least 56 resonances, 
that showed a good chemical shift dispersion, and narrow line widths of about 
0.5–1.0 ppm. However, the same spectrum for Sc237 displayed a different 
pattern, and the resonances appeared to be broadened when compared to 
263K. Still, there appears to be a significant degree of structural similarity 
between the two strains. A set of five backbone resonances (Fig. 25, see 
arrow-heads) are shifted between the two spectra, but the overall pattern is 
very-well preserved. Thus, at least some parts of the 3D structures appear to 
be almost identically conserved between Sc237 and 263K.  
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 Finally, we compared the structures of all reaction products that were 
generated from the prions strains Sc237 and 263K (table 9). For this purpose, 
we recorded [13C,13C] DARR spectra using a DARR mixing time of only 
15 ms, where correlation peaks are observed only for neighbouring 13C atoms 
within individual amino acid side chains. Figure 26A shows the spectral region 
that contains the 13C/13C correlation peaks of glutamic acid and of glutamine 
side chains. The reaction products of 263K-953 and of 263K-378 contain the 
same peak pattern, which provides very strong evidence that the same 
conformation was selected under both experimental conditions. However, 
when the three Sc237 amplification products are compared, it becomes 
immediately evident, that each peak pattern is distinct. Unexpectedly, the 
product Sc237-189 contains virtually the identical peak pattern as the 
products 263K-953 and 263K-378. This provides substantial evidence that the 
263K conformation is also present in the original Sc237 prion isolate. In 
addition, while the reaction products Sc237-953 and Sc237-378 look very 
similar in this spectral region, they can also be distinguished by one shifting 
resonance (see arrow heads). These structural differences are also readily 
evident from the two corresponding 1D-traces shown below the 2D spectra 
regions.   
In order to further support the presence of three distinct conformations in the 
total of five different reaction products, we also compared the corresponding 
13C/13C and 13C/13C correlations of threonine side-chains (Fig. 26B). Also 
here the pattern of 263K-953, 263K-378, and Sc237-189 are nearly identical. 
The distinction of Sc237-953 and Sc237-378 is even more evident in this 
spectral region, because up to three additional sets of resonances can be 
identified for Sc237-953 (see arrow heads).  
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Finally, it has to be noted that the 263K peak pattern has been obtained under 
three substantially different shearing conditions, and thus shearing per se 
does not determine the structure that is generated. This is also evident from 
the spectrum of a spontaneously generated aggregate (spont-189), that is 
indicative of an inhomogeneous aggregate. Thus these ssNMR-data provide 
the experimental proof that the amplification products generated by SSA are 
determined by the utilized initial seed and its conformational composition. In 
summary, these NMR data provide very strong evidence of the co-existence 
of three distinct prion conformations in the Sc237 prion isolate. Importantly, 
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the 263K prion isolate appears to contain only one single conformation, which 
is also a subset of the Sc237 prion isolate.   
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5 Discussion 
In order to investigate the still obscure attributes related to the structure of 
prions, it was necessary to obtain sufficiently large amounts of recombinant 
PrPres. The goal of the project was first to optimize the in vitro amplification 
conditions of rec. PrPres using full length (23-230) hamster prion protein as a 
substrate. Further these rec. prion aggregates were characterized, primarily by 
solid state NMR which was followed by electron microscopy and detection by 
proteinase K resistance on a silver stained gel.  
 
5.1 Recent Advances in Prion Amplification 
Till date, several in vitro methods for prion protein conversion and amplification 
have been reported. Soto and colleagues developed the assay called “protein 
misfolding cyclic amplification (PMCA)” reaction, where in the presence of 
infectious prions, native PrPC from brain homogenates was converted into an 
aggregated PrPres using a series of incubation and sonication cycles. The 
method is sensitive to detect as little as 1 ag of PrPsc (Saa, Castilla et al. 
2006). However, the requirement for brain-derived PrPC as the amplification 
substrate makes the method inapt for generating prions using recombinant 
PrPC as a substrate. Moreover, there was great degree of variability in the 
vibrational energy distribution to the samples (Atarashi, Sano et al. 2011). To 
further add up, (Castilla et al., 2006) stated that for efficient prion propagation 
using PMCA, co-factors present in brain homogenates were vital. Bacterially 
expressed recombinant PrPC lacks glycosylation and the 
glycophosphatidylinositol (GPI) anchor which furthermore raised the problem 
of using rec. PrPC. Still, in 2007, Atarashi et al. attempted to replace the 
substrate from normal brain homogenate to rec. PrP using the standard PMCA 
set-up (Atarashi, Moore et al. 2007). This method called rPrP-PMCA was able 
to detect as little as 50 ag of PrPSc. However, the problems associated with 
sonication as a means of fragmentation still existed. Soon in 2008, Caughey 
and co-workers developed a method where they substituted sonication with 
shaking in a thermoshaker and showed prion amplification using rec. PrPC as a 
substrat. This method was termed as  quaking-induced conversion (QuIC) 
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assay (Atarashi, Wilham et al. 2008). It has the potential to detect sub-
femtogram amounts of PrPSc within a day. The establishment of QuIC assay 
was found to be a great success as it improved the overall feasibility of the 
experimental set-up.  
 
However, initial work done in our lab showed that the conversion efficiency 
both by ultrasound and by shaking is highly volume dependent and yields of 
the protease resistant prion protein are not consistent (data not shown). 
Moreover, the typical reaction volume used in these assays was 100 µl 
which was not sufficient for solid state NMR analysis. So there persists a 
need for the development of a method by which rec. PrPres samples can be 
prepared in a homogenous and reproducible manner in sufficient quantities 
for further structural analysis. 
 
5.2 Development of Selective Shearing Amplification 
(SSA)  
Keeping the needs and perspectives in mind, an instrument was built in our 
group by Dr. Thorsten Lührs called as “SSA Array” (see Methods).  Based on 
shear induced fragmentation applied by shear generators (7F, Heidolph), we 
can conformationally select PrPSc from the brain and amplify the seed specific 
aggregates using rec. hamster prion protein as a substrate. Most importantly, 
we can scale-up the volume of the reactions up to 200 ml without affecting the 
rate of amplification or loss in the yield. With the development of the 
instrument, we initially focussed on establishing an optimized method for rec. 
PrP conversion which resulted in consistent and reproducible amplification, 
while assessing whether all the key parameters (seed and substrate 
concentration, cycle time, detergent concentration etc.) would lead to a 
positive or negative effect on overall levels of rec. PrPres amplification. 
 
Using this assay, we could not only amplify specific prion seeds with 
recombinant PrP but also improved the sensitivity of prion detection by using 
half the concentration of substrate in comparison to the QuIC assay i.e., 50 
µg/ml (Fig. 4.2). This in turn makes the method economically efficient as for 
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NMR studies we have to isotope label the protein with either 15N or 13C which 
is very expensive.  
 
Additionally, shear induced fragmentation of seeds for PrPres amplification 
using rec. PrPC as a substrate allowed clear discrimination between PrPSc-
seeded and non-seeded reaction products (Fig. 4.5). Initial trials revealed that 
in the presence of 0.1% SDS and 0.1% Triton X-100, 5 seconds processing in 
every 5 minutes resulted in spontaneous (non-seeded) conversion of 
bacterially expressed recombinant hamster PrPC to proteinase K (PK) resistant 
forms. Interestingly, these spontaneously generated forms were totally 
supressed by finely tuning the processing conditions where the seed 
fragmentation was precisely controlled. 
 
Furthermore, SSA also showed the potential to differentiate between two 
closely related prion strains – Sc237 and 263K by the kinetic analysis of in 
vitro selected PrPres. The strain 263K showed only one prominent PrPres 
population near the maximal processing frequency whereas in Sc237 three 
distinct optima were identified (Fig. 4.6). This indicated that rec. PrPres 
amplification for kinetic selection of prion seeds is not influenced by shearing 
mechanisms and the overall seed conformations are not altered by shearing 
itself. 
 
Moreover, we observed that rec. PrPres generated by SSA can be perpetuated 
indefinitely without any loss of seeding activity (Fig. 4.8).  Some of the 
reactions e.g. those running at 189 Hz., 378 Hz. and 953 Hz. were propagated  
up to round 45 corresponding to a total dilution of  1.4 x 10-78 relative to the 
initial seed. This provided a very strong proof for the efficiency and robustness 
of SSA. Thereby we were able to produce virtually unlimited amounts of 
isotope labelled and conformationally selected rec. PrPres aggregates from 
both Sc237 and 263K prions (Table 9). With these aggregates we were able to 
record high quality solid state NMR spectra which indicated that the structural 
determination of PrPres aggregates is possible (Figures 24-26).  
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5.3 Conformations of Recombinant PrPres 
The protein only hypothesis (see section 1.2) claims that the proteins 
conformation of PrPSc is necessary and sufficient to transmit prion diseases 
between susceptible hosts. In particular the work of Prusiner and Co-workers 
(Legname et al. 2004) provided strong indications that the protein only 
hypothesis might be true. They used de novo generated recombinant PrP 
fibrils to inoculate transgenic syrian hamster that over expressed PrP(90-230) 
16-fold relative to wild-type hamsters. After extended incubation times of >500 
days these hamster succumbed to prion disease. However, to date there it is 
not clear how the type of fibril relates to the prion diseases that they caused. In 
particular the serial propagation of the  de novo induced hamster prion disease 
was accompanied by a successive shortening in incubation times, and two 
distinct novel hamster prion strains have been identified from these 
transmissions and compared to known prion strains (Legname, Nguyen et al. 
2006). Moreover, the solid state NMR spectra of the utilized hamster PrP fibrils 
were analysed and revealed an overall poor spectral quality that was indicative 
of conformationally mixed aggregates (Tycko, Savtchenko et al. 2010). It is 
therefore not clear whether any of the conformations that was administered to 
the hamsters caused the disease, or alternatively, whether these aggregated 
triggered the spontaneous de novo generation of prions in the brain. 
In order to see whether our conformationally selected PrPres aggregates 
contained distinct individual conformations, we analysed all [13C,15N]-labeled 
samples by solid state NMR spectroscopy (see section 4.3). Upon first 
inspection of the resulting 2D-NMR spectra (Figure 24), it became immediately 
clear that SSA had produced homogeneously structured PrPres aggragtes. We 
compared our data to previously published ssNMR-spectra of recombinant 
hamster PrP fibrils that had been used to induce prion diseasae in hamsters 
(Tycko, Savtchenko et al. 2010). It becomes readily evident that the 
conformation of our strain specifically selected PrPres differs substantially from 
those other fibrils. In particular in all our samples, resonances corresponding to 
four isoleucines with narrow line width can readily be identified in the 13C 
spectral range between 12 and 18 ppm. Corresponding resonances are in 
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different positions of even absent in the data of Tycko et al.  This is particularly 
noteworthy because all four isoleucine residues of hamster PrP are located in 
the C-terminal domain, which is alpha-helical (α2 and α3) in PrP (compare 
Figures 4. And 5.). Thus, significant structural differences exist between our 
samples and previously investigated PrP fibrils. 
When we compared the ssNMR spectra from all [13C, 15N] labelled PrPres 
reaction products it became clear that in all cases homogeneous samples 
were obtained. This is particularly noteworthy because a total of sixty individual 
reactions of 10 ml volume spanning five serial passages were pooled required 
to generate ~30 mg of [13C, 15N] labelled PrPres for each solid state NMR. If 
there were any significant variability in the conformation selective amplification 
between the individual reactions, this would inevitably lead structurally 
heterogeneous samples and correspondingly poor quality NMR spectra. 
However, all NMR-spectra were of very good or even excellent quality, which 
in itself provides very clear evidence of the robustness of the approach 
established here for the generation of conformationally selected recombinant 
prion samples.  
We were able to identify three different conformations present in the five 
selected conformational products. From the hamster 263K prion strain, we 
prepared the solid state NMR sample at two different processing frequencies 
(378 Hz and 953 Hz), which resulted into the amplification of same PrPres 
conformation in both cases (Fig. 26). The amplification rate at 953Hz was 
substantially faster than at 378Hz (Fig. 16D). This clearly indicated that (i) 
shearing itself does not induce or alter the selected conformations, and (ii) the 
amplified conformation does also not depend on the amplification rate. Thus, 
using SSA it appears evident that the obtained product is determined by the 
prion strain that is used as a seed.  
To further investigate the conformation selection, we also amplified rec. PrPres 
under three different shearing conditions for NMR analysis using the Sc237 
strain as a seed. Under all condition, distinguishable PrPres conformations were 
obtained. While the products obtained with 378 Hz and 953 Hz rotor frequency 
(see methods), lead to the amplification of conformations that were distinct 
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from 263K, the reaction product generated at 189Hz rotor frequency generated 
PrPres aggregates that were essentially undistinguishable from the 263K 
conformation. From this date we conclude that the 263K strain contain only 
one single prion conformation, but that the Sc237 prion strain is a mixture of 
different prion conformation that appear to co-exist in vivo. The 263K 
conformation is thus also a sub-set of the Sc237 conformational mix.  
We also compared these rec. PrP aggregates using transmission electron 
microscopy (TEM) at three different frequencies for Sc237 − 189 Hz., 378 Hz. 
and 953 Hz. Overall, we observed slightly different morphologies for these 
aggregates which is due to different lateral association that depends clearly on 
the shearing conditions. At higher frequencies e.g. 953 Hz. we tend to induce 
stronger lateral association with prion samples and hence the appearance of 
these aggregates resemble more like prion rods  which was published by 
Prusiner (Prusiner, McKinley et al. 1983). However, at lower frequencies e.g. 
189 Hz. the fibrils don’t co-aggregate strongly, rather there is a collection of 
broken or dissociated smaller fragments. So there is a shear induced fibril - 
fibril association effect that resulted in morphological variation.  
For 263K, we compared the morphologies at two different shearing conditions 
− 378 Hz. and 953 Hz. In contradiction to the Sc237 strain, 263K showed no 
difference at both the frequencies. This suggests the evidence for visualising 
strain differences in prions using shear induced fragmentation.  The results of 
silver staining also supported the above confirmed observation where 263K 
contained primarily only one PrPres population (Fig. 4.6). Thus overall, the 
aggregate morphology appear to be closely similar for 263K but there may be 
a variation in the degree of lateral association which can be readily explained 
as a shear induced fibrilar-fibrilar aggregation effect. 
In summary, our experimental observations on conformationally selected 
recombinant PrPres are consistent with the history of these two prion isolates. 
The Sc237 strain has originally been derived from the inter-species 
transmission of goat scrapie to hamsters. During the same passage history, 
the 236K strain has been obtained by limiting dilution passages in syrian 
hamsters (clonal prion selection), while Sc237 has apparently never been 
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clonally selected (Kimberlin and Marsh 1975; Marsh and Kimberlin 1975; 
Kimberlin 1976; Kimberlin and Walker 1977). This suggests that the Sc237 
prion strain has always contained multiple prion conformations, and that the 
263K conformation has coincidentally been selected from that mixture. Thus, it 
appears possible to investigate prion strain inheritance and strain selection by 
SSA and solid-state NMR. 
 
5.4 Future Perspectives 
The major limitation of the PMCA and QuIC methods was that the detection of 
protease resistant prion seeded products was done by the time consuming 
western blotting. By amyloid seeding assay (ASA), an attempt was made to 
fasten up the whole detection procedure by using fluorescent dye thioflavin T 
(ThT), that displays enhanced fluorescence upon binding to amyloid fibrils 
(Colby, Zhang et al. 2007). However, ASA often leads to spontaneous 
formation of rec. PrP fibrils. Later following the same principle of ASA i.e. 
detection through fluorescent ThT, another assay was established called real-
time (RT)-QuIC which was an amalgamation of QuIC and ASA. RT-QuIC not 
only provided the faster means for prion detection but also reduced 
spontaneous rec. PrP fibril formation. Nonetheless, all these methods still pose 
a problem to scale-up the reaction volume which is distinctly a desideratum for 
making solid state NMR sample for structural analysis. With our assay, we 
overcame the problem of increasing reaction volume without affecting the yield 
of prion amplification. However, the current method involved PrPres detection 
by silver stained SDS gel electrophoresis. So, there continues to be a need for 
further technical development of the method that will allow rapid detection of 
prions. For dealing this issue, in future we will focus our attention towards 
detection by fluorescent dye ThT, which not only reduce the time for detection 
but will be more handy and flexible.  
Already now we can distinguish the two prion strains Sc237 and 263K based 
on their conformational composition. At the time of writing this thesis 
transmissions in hamsters of the conformationally selected aggregates are on-
going. The results from these experiments will reveal whether the selected 
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recombinant conformations are also infectious, and whether the identified 
conformations are sufficient to induce prion disease. 
With this work, a basis has been generated that will allow to investigate the 
molecular 3D structures of prions in relation to the disease phenotype 
associated with the initial prion seed. Potentially, it might even be possible to 
determine how conformations change during interspecies transmissions. Thus, 
the public health concern about TSE diseases could be readily addressed by 
the underlying molecular mechanism. Since we can make homogenous 
conformations from predefined hamster prions as seeds, it would seem also 
possible to structurally investigate seeds from other neurodegenerative 
diseases like Alzheimer’s and Parkinson’s disease using similar approaches 
as established in this work. 
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